STOCK TITAN

Fabric.AI Q3 loss widens to $4.91M on zero revenue

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Fabric.AI, Inc. (FABC) reported no revenue and a net loss of $4.91 million for the three months ended September 30, 2026, versus $2.76 million a year earlier. For the nine months, net loss was $19.80 million, compared with $16.06 million, and cash used in operating activities was $12.56 million versus $6.05 million.

The company says it began a strategic shift toward fabless semiconductor technologies for AI data-center infrastructure. Under an April 27, 2026 joint development and license agreement with Kopin, it received rights to use Kopin technology for MicroLED-based optical interconnects; the license was recognized as a $17.24 million intangible asset. Fabric.AI says it expects future revenue from semiconductors made using the technology.

In an April 2026 private placement, Fabric.AI raised $21.5 million in gross proceeds through Series K convertible preferred stock. The financing also included warrants; as of September 30, 2026, 19,247 Series K preferred shares and 8,565,737 Series K warrants were outstanding. The preferred stock converts at $2.51 per common share, and the warrants have a $2.51 exercise price. At quarter-end, cash and cash equivalents were $2.15 million and marketable securities were $13.85 million.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss widened to $19.80 million from $16.06 million.
  • Major pointOperating cash used increased to $12.56 million from $6.05 million.
  • Minor pointQuarterly net loss widened to $4.91 million from $2.76 million.

Filing Explained

The Series J terms leave the obligation to issue shares for noncash issuances, including preferred conversions, outside the stated 50 million dollar adjustment cap.

Form 10-Q is an unaudited quarterly report; the company reports that it issued 3,530 additional Series J preferred shares to Kopin under anti-dilution provisions during the nine months ended September 30, 2026, with 4,260 Series J shares outstanding at quarter-end. Those preferred shares may be converted into common stock at the holder’s option at $2.51 per share; conversion would increase the common share count and reduce existing holders’ percentage ownership. The original maximum issuance was 291,049 common shares, but the terms allow increases for defined events, and the $50 million cap on certain adjustments does not limit shares owed for noncash issuances, including preferred conversions.

At September 30, 19,247 Series K preferred shares remained convertible into up to 7,856,720 common shares, and 8,565,737 Series K warrants were outstanding. Series K preferred shares accrue dividends at 7% annually, compounded quarterly, and holders may require cash redemption at a specified premium upon triggering events. The filing reports 7,456,987 common shares outstanding at September 30 and 7,591,447 as of November 13, 2026.

Revenue $0 Three months ended September 30, 2026
Net loss $4.91 million Three months ended September 30, 2026
Net loss $19.80 million Nine months ended September 30, 2026
Net cash used in operating activities $12.56 million Nine months ended September 30, 2026
Cash and cash equivalents $2.15 million As of September 30, 2026
Marketable securities $13.85 million As of September 30, 2026
License intangible asset $17.24 million Recognized in connection with the Kopin agreement
Series K gross proceeds $21.5 million April 2026 private placement
fabless semiconductor technologies technical
"design and development of fabless semiconductor technologies"
A business model and set of practices where a company designs and develops semiconductor chips but outsources the actual wafer fabrication and packaging to specialized foundries and contractors. Like a fashion designer who creates clothes but hires factories to sew them, fabless firms concentrate on research, design and intellectual property while relying on external manufacturers; that structure matters to investors because it changes capital needs, profit drivers, supply-chain risk and strategic partnerships.
MicroLED-based optical interconnects technical
"MicroLED-based optical interconnect technologies"
Tiny light-emitting components called microLEDs are used to send data between chips or circuit boards using pulses of light instead of electrical signals; that combination is called microLED-based optical interconnects. Investors should care because replacing metal wires with light can make computing systems faster, cooler and more energy-efficient—like swapping congested city streets for dedicated express lanes—potentially lowering operating costs and enabling higher-performance products that drive revenue growth.
Series K Convertible Preferred Stock financial
"21,500 shares of newly designated Series K Convertible Preferred Stock"
anti-dilution liability financial
"recognized an anti-dilution liability"
mezzanine equity financial
"classified as temporary (mezzanine) equity"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
Level 3 financial
"classified within Level 3 of the fair value hierarchy"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were FABC's revenue and net loss in Q3 2026?

Fabric.AI reported $0 revenue and a $4.91 million net loss for the three months ended September 30, 2026, compared with a $2.76 million net loss in the year-earlier quarter.

How much did FABC raise in its Series K financing?

Fabric.AI received $21.5 million in gross proceeds from its Series K private placement. It issued 21,500 shares of Series K preferred stock; as of September 30, 2026, 19,247 remained outstanding and 8,565,737 Series K warrants were outstanding.

What technology is Fabric.AI developing with Kopin?

Fabric.AI and Kopin are jointly developing MicroLED-based optical interconnect technologies and related semiconductor products. Fabric.AI identifies its initial product under development as the Neural I/o chip, an optical interconnect.

What did Fabric.AI issue Kopin for the technology license?

Fabric.AI issued Kopin 730 shares of Series J Convertible Preferred Stock as consideration for the license. The shares constituted 19.9% of pro forma fully diluted common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001086745 0001086745 2026-01-01 2026-09-30 0001086745 2026-11-13 0001086745 2026-09-30 0001086745 2025-12-31 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2026-09-30 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesIMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesIMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesHMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesHMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesHThreeMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesHThreeMember 2025-12-31 0001086745 FABC:ConvertiblePreferredStockSeriesHSixMember 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesHSixMember 2025-12-31 0001086745 2026-07-01 2026-09-30 0001086745 2025-07-01 2025-09-30 0001086745 2025-01-01 2025-09-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-12-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-12-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-12-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-12-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001086745 us-gaap:CommonStockMember 2025-12-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001086745 us-gaap:RetainedEarningsMember 2025-12-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-03-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-03-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-03-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-03-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001086745 us-gaap:CommonStockMember 2026-03-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001086745 us-gaap:RetainedEarningsMember 2026-03-31 0001086745 2026-03-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-06-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-06-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-06-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-06-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001086745 us-gaap:CommonStockMember 2026-06-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001086745 us-gaap:RetainedEarningsMember 2026-06-30 0001086745 2026-06-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2024-12-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2024-12-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2024-12-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2024-12-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001086745 us-gaap:CommonStockMember 2024-12-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001086745 us-gaap:RetainedEarningsMember 2024-12-31 0001086745 2024-12-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-03-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-03-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-03-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-03-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001086745 us-gaap:CommonStockMember 2025-03-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001086745 us-gaap:RetainedEarningsMember 2025-03-31 0001086745 2025-03-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-06-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-06-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-06-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-06-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001086745 us-gaap:CommonStockMember 2025-06-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001086745 us-gaap:RetainedEarningsMember 2025-06-30 0001086745 2025-06-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-01-01 2026-03-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-01-01 2026-03-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-01-01 2026-03-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-01-01 2026-03-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001086745 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001086745 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001086745 2026-01-01 2026-03-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-04-01 2026-06-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-04-01 2026-06-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-04-01 2026-06-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-04-01 2026-06-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001086745 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001086745 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001086745 2026-04-01 2026-06-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-07-01 2026-09-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001086745 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001086745 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-01-01 2025-03-31 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-01-01 2025-03-31 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-01-01 2025-03-31 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-01-01 2025-03-31 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001086745 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001086745 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001086745 2025-01-01 2025-03-31 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-04-01 2025-06-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-04-01 2025-06-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-04-01 2025-06-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-04-01 2025-06-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001086745 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001086745 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001086745 2025-04-01 2025-06-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-07-01 2025-09-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001086745 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001086745 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2026-09-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2026-09-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2026-09-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2026-09-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001086745 us-gaap:CommonStockMember 2026-09-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001086745 us-gaap:RetainedEarningsMember 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember FABC:TemporaryEquityMember 2025-09-30 0001086745 FABC:SeriesJPreferredStockMember FABC:TemporaryEquityMember 2025-09-30 0001086745 FABC:SeriesIPreferredStockMember FABC:TemporaryEquityMember 2025-09-30 0001086745 FABC:SeriesHSevenPreferredStockMember FABC:TemporaryEquityMember 2025-09-30 0001086745 us-gaap:SeriesHPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001086745 FABC:SeriesHThreePreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001086745 FABC:SeriesHSixPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001086745 us-gaap:CommonStockMember 2025-09-30 0001086745 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001086745 us-gaap:RetainedEarningsMember 2025-09-30 0001086745 2025-09-30 0001086745 2026-04-27 0001086745 us-gaap:SubsequentEventMember 2026-11-13 0001086745 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0001086745 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001086745 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0001086745 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001086745 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001086745 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001086745 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001086745 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001086745 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001086745 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001086745 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001086745 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001086745 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001086745 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001086745 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001086745 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001086745 FABC:USTreasuryBillsMember 2026-09-30 0001086745 FABC:USTreasuryBillsMember 2025-12-31 0001086745 us-gaap:USGovernmentDebtSecuritiesMember 2026-09-30 0001086745 us-gaap:USGovernmentDebtSecuritiesMember 2025-12-31 0001086745 FABC:KopinJointDevelopmentAgreementMember 2026-09-30 0001086745 FABC:KopinJointDevelopmentAgreementMember FABC:SeriesJConvertiblePreferredStockMember 2026-09-30 0001086745 FABC:KopinJointDevelopmentAgreementMember FABC:SeriesJConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001086745 FABC:LicenseRightMember 2026-09-30 0001086745 us-gaap:SeriesHPreferredStockMember 2015-06-30 0001086745 FABC:SeriesHThreePreferredStockMember 2017-03-30 0001086745 FABC:SeriesHSixConvertibePreferredStockMember 2020-02-05 0001086745 FABC:SeriesHSixConvertibePreferredStockMember 2020-02-05 2020-02-05 0001086745 FABC:SeriesHSixConvertibePreferredStockMember us-gaap:CommonStockMember 2020-02-05 2020-02-05 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2023-08-07 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2023-08-07 2023-08-07 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2023-08-10 2023-08-10 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001086745 FABC:SeriesHSevenConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2025-08-04 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2025-08-04 2025-08-04 0001086745 FABC:SeriesIWarrantsMember 2025-08-04 0001086745 FABC:SeriesIWarrantsMember 2025-08-08 2025-08-08 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2025-12-31 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001086745 FABC:SeriesIPlacementAgentWarrantsMember 2025-01-01 2025-12-31 0001086745 FABC:SeriesIWarrantsMember 2025-01-01 2025-12-31 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember srt:MinimumMember 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember srt:MaximumMember 2026-09-30 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesIConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2026-04-27 2026-04-27 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2026-04-27 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2026-01-01 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesJMember 2026-07-01 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-04-27 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-04-27 2026-04-27 0001086745 FABC:SeriesKPreferredStockAndWarrantsMember 2026-04-27 2026-04-27 0001086745 FABC:SeriesKWarrantsMember 2026-04-27 2026-04-27 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-07-01 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesKPreferredStockAndWarrantsMember 2026-07-01 2026-09-30 0001086745 FABC:SeriesKPreferredStockAndWarrantsMember 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember 2026-09-30 0001086745 FABC:SeriesKPreferredStockMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesHSevenWarrantsMember 2023-08-30 0001086745 FABC:SeriesHSevenWarrantsMember 2023-08-31 0001086745 FABC:SeriesHSevenWarrantsMember FABC:TwoThousandTwentyFiveReserseStockSplitMember 2023-08-30 0001086745 FABC:SeriesHSevenWarrantsMember FABC:TwoThousandTwentyFiveReserseStockSplitMember 2023-08-31 0001086745 FABC:SeriesKPreferredStockMember 2026-04-27 0001086745 FABC:SeriesKPreferredStockMember 2026-09-30 0001086745 FABC:SeriesIWarrantsMember 2025-08-06 2025-08-06 0001086745 FABC:SeriesIWarrantsMember 2025-08-06 0001086745 FABC:SeriesIPlacementAgentWarrantsMember 2025-08-06 2025-08-06 0001086745 FABC:SeriesIPlacementAgentWarrantsMember 2025-01-01 2025-12-31 0001086745 FABC:SeriesIPlacementAgentWarrantsMember 2025-12-31 0001086745 FABC:SeriesKPreferredStockMember 2026-04-30 0001086745 FABC:SeriesKPreferredStockMember srt:MinimumMember 2026-04-30 0001086745 FABC:SeriesKPreferredStockMember srt:MaximumMember 2026-04-30 0001086745 FABC:SeriesIWarrantsAndSeriesHSevenWarrantsMember 2025-08-26 2025-08-26 0001086745 FABC:SeriesIWarrantsMember 2025-08-26 2025-08-26 0001086745 FABC:SeriesHSevenWarrantsMember 2025-08-26 2025-08-26 0001086745 FABC:SeriesKWarrantsMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesKWarrantsMember 2026-09-30 0001086745 FABC:SeriesKWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001086745 FABC:PlacementAgentWarrantsMember 2026-01-01 2026-09-30 0001086745 FABC:SeriesKPrivatePlacementMember 2026-01-01 2026-09-30 0001086745 FABC:WaiverWarrantsMember 2026-04-01 2026-04-30 0001086745 FABC:WaiverWarrantsMember 2026-04-30 0001086745 FABC:AltucherConsultingAgreementMember 2025-08-04 0001086745 FABC:AltucherConsultingAgreementMember srt:MinimumMember 2025-08-04 0001086745 FABC:AltucherConsultingAgreementMember srt:MaximumMember 2025-08-04 0001086745 FABC:AltucherConsultingAgreementMember 2025-08-04 2025-08-04 0001086745 FABC:AltucherConsultingAgreementMember srt:MaximumMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember FABC:FirstTrancheWarrantMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember FABC:SecondTrancheWarrantMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember FABC:ThirdTrancheWarrantMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember FABC:FourthTrancheWarrantMember 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember 2026-04-26 2026-04-26 0001086745 FABC:AltucherConsultingAgreementMember 2026-04-26 0001086745 FABC:AltucherConsultingAgreementMember srt:MinimumMember 2026-04-26 0001086745 FABC:AltucherConsultingAgreementMember srt:MaximumMember 2026-04-26 0001086745 FABC:AltucherConsultingAgreementMember 2026-04-27 2026-04-27 0001086745 FABC:AltucherConsultingAgreementMember srt:MinimumMember 2026-04-27 0001086745 FABC:FirstTrancheWarrantMember FABC:AltucherConsultingAgreementMember 2026-09-30 0001086745 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-09-30 0001086745 FABC:FirstTrancheWarrantsMember 2026-07-01 2026-09-30 0001086745 FABC:FirstTrancheWarrantsMember 2026-01-01 2026-09-30 0001086745 FABC:ConvertiblePreferredStockSeriesKMember 2026-04-26 0001086745 FABC:SeriesKWarrantsMember 2026-04-26 0001086745 FABC:SeriesKWarrantsMember 2026-04-27 0001086745 FABC:SeriesKPreferredStockAndWarrantsMember 2026-04-26 0001086745 FABC:SeriesKPreferredStockAndWarrantsMember 2026-04-27 0001086745 FABC:NonEmployeeDirectorMember us-gaap:EmployeeStockOptionMember 2026-07-07 2026-07-07 0001086745 FABC:NonEmployeeDirectorMember us-gaap:EmployeeStockOptionMember 2026-10-07 2026-10-07 0001086745 FABC:NonEmployeeDirectorMember us-gaap:EmployeeStockOptionMember srt:ScenarioForecastMember 2027-01-07 2027-01-07 0001086745 FABC:NonEmployeeDirectorMember us-gaap:EmployeeStockOptionMember srt:ScenarioForecastMember 2027-04-07 2027-04-07 0001086745 FABC:NonEmployeeDirectorMember us-gaap:EmployeeStockOptionMember srt:ScenarioForecastMember 2027-07-07 2027-07-07 0001086745 FABC:EmployeesMember us-gaap:EmployeeStockOptionMember 2026-08-14 2026-08-14 0001086745 FABC:EmployeesMember us-gaap:EmployeeStockOptionMember 2026-08-14 0001086745 FABC:EmployeesMember us-gaap:EmployeeStockOptionMember 2026-06-18 2026-06-18 0001086745 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0001086745 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001086745 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2026-06-18 2026-06-18 0001086745 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2026-06-18 0001086745 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001086745 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2026-04-01 2026-06-30 0001086745 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0001086745 us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0001086745 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0001086745 us-gaap:RestrictedStockMember 2026-09-30 0001086745 us-gaap:EmployeeStockOptionMember 2026-09-30 0001086745 FABC:SeriesIDerivativeLiabilityMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2026-09-30 0001086745 us-gaap:USTreasuryAndGovernmentMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel1Member FABC:USTreasuryNotesOverNinetyDaysMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel2Member FABC:USTreasuryNotesOverNinetyDaysMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member FABC:USTreasuryNotesOverNinetyDaysMember 2026-09-30 0001086745 FABC:USTreasuryNotesOverNinetyDaysMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel1Member FABC:AntiDilutionLiabilityMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel2Member FABC:AntiDilutionLiabilityMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member FABC:AntiDilutionLiabilityMember 2026-09-30 0001086745 FABC:AntiDilutionLiabilityMember 2026-09-30 0001086745 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeLiabilities 2026-09-30 0001086745 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeLiabilities 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeLiabilities 2026-09-30 0001086745 us-gaap:DerivativeLiabilities 2026-09-30 0001086745 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001086745 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001086745 FABC:SeriesIMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001086745 FABC:SeriesHSevenMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001086745 FABC:SeriesJAntidilutionMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001086745 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001086745 FABC:SeriesIMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0001086745 FABC:SeriesHSevenMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0001086745 FABC:SeriesJAntidilutionMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0001086745 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0001086745 FABC:SeriesIMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001086745 FABC:SeriesHSevenMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001086745 FABC:SeriesJAntidilutionMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001086745 us-gaap:MonteCarloModelMember FABC:MeasurementInputPenaltyDividendRateMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember FABC:MeasurementInputPenaltyDividendRateMember 2025-12-31 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputDefaultRateMember 2026-09-30 0001086745 us-gaap:MonteCarloModelMember us-gaap:MeasurementInputDefaultRateMember 2025-12-31 0001086745 FABC:SegmentMember 2026-07-01 2026-09-30 0001086745 FABC:SegmentMember 2026-01-01 2026-09-30 0001086745 FABC:KopinCorporationMember 2026-01-01 2026-09-30 0001086745 FABC:KopinCorporationMember 2026-09-30 0001086745 FABC:GilbertVillarrealMember 2026-01-01 2026-09-30 0001086745 FABC:KopinCorporationMember FABC:ResearchAndDevelopmentExpensesMember 2026-07-01 2026-09-30 0001086745 FABC:KopinCorporationMember FABC:ResearchAndDevelopmentExpensesMember 2025-07-01 2025-09-30 0001086745 FABC:MichaelMurrayMember FABC:GeneralAndAdministrativeExpensesMember 2026-07-01 2026-09-30 0001086745 FABC:MichaelMurrayMember FABC:GeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:ResearchAndDevelopmentExpensesMember 2026-07-01 2026-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:ResearchAndDevelopmentExpensesMember 2025-07-01 2025-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:GeneralAndAdministrativeExpensesMember 2026-07-01 2026-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:GeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0001086745 FABC:KopinCorporationMember FABC:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-09-30 0001086745 FABC:KopinCorporationMember FABC:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-09-30 0001086745 FABC:MichaelMurrayMember FABC:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-09-30 0001086745 FABC:MichaelMurrayMember FABC:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0001086745 FABC:KopinCorporationMember FABC:AccruedExpensesAndOtherCurrentLiabilitiesMember 2026-09-30 0001086745 FABC:KopinCorporationMember FABC:AccruedExpensesAndOtherCurrentLiabilitiesMember 2025-12-31 0001086745 FABC:ElectricPowerEnergyMember FABC:AccruedExpensesAndOtherCurrentLiabilitiesMember 2026-09-30 0001086745 FABC:ElectricPowerEnergyMember FABC:AccruedExpensesAndOtherCurrentLiabilitiesMember 2025-12-31 0001086745 FABC:AssetPurchaseAgreementMember 2026-06-11 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember 2026-04-27 2026-04-27 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember 2026-01-01 2026-09-30 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember 2026-09-30 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember 2026-07-01 2026-09-30 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember srt:MinimumMember 2026-04-27 2026-04-27 0001086745 FABC:JointDevelopmentAndLicenseAgreementMember srt:MaximumMember 2026-04-27 2026-04-27 0001086745 FABC:MurrayConsultingAgreementMember FABC:KopinCorporationMember 2026-08-14 0001086745 FABC:MurrayConsultingAgreementMember 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure FABC:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission file number: 001-34643

 

FABRIC.AI, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   98-0204758

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

1185 Avenue of the Americas,

New York, NY

  10036
(Address of principal executive offices)   (Zip Code)

 

(512) 994-4917

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   FABC   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2026, the registrant had 7,591,447 shares of common stock, par value $0.0001 per share, outstanding.

 

 

 

 

 

 

FABRIC.AI, INC.

QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2026

 

TABLE OF CONTENTS

 

Part I – Financial Information F-1
   
Item 1 Financial Statements (Unaudited) F-1
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 1
Item 3 Quantitative and Qualitative Disclosures about Market Risk 10
Item 4 Controls and Procedures 10
   
Part II – Other Information 11
   
Item 1 Legal Proceedings 11
Item 1A Risk Factors 11
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 16
Item 3 Defaults Upon Senior Securities 16
Item 4 Mine Safety Disclosures 16
Item 5 Other Information 16
Item 6 Exhibits 17

 

i

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

FABRIC.AI, INC.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

    Page
Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025   F-2
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)   F-3
Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)   F-4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited)   F-5
Notes to Condensed Consolidated Financial Statements (Unaudited)   F-6

 

F-1

 

 

FABRIC.AI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   September 30,   December 31, 
   2026   2025 
ASSETS          
Current assets:          
Cash and cash equivalents  $2,152,690   $4,981,798 
Restricted cash   5,102,691    110,264 
Marketable securities   13,847,648    3,168,362 
Prepaid expenses and other current assets   742,307    951,175 
Total current assets   21,845,336    9,211,599 
           
Operating lease – right-of-use asset   95,515    227,171 
Intangible assets   17,238,716    — 
Digital assets   —    1,948,999 
Deposits and other assets   —    20,883 
Total assets  $39,179,567   $11,408,652 
           
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $1,374,351   $916,685 
Accrued expenses and other current liabilities   1,943,965    476,592 
Current portion lease obligation – operating lease   98,617    250,517 
Total current liabilities   3,416,933    1,643,794 
           
Derivative liability   89,000    19,000 
Anti-dilution liability   11,672,166    — 
Lease obligation - operating lease, net of current portion   —    33,225 
Total liabilities   15,178,099    1,696,019 
           
Mezzanine equity:          
Redeemable Series H-7 Convertible Preferred Stock, ($0.0001 par value per share and $1,000 face value per share; authorized - 22,000 shares; issued and outstanding – 0 and 1,180 shares, at September 30, 2026 and December 31, 2025, respectively).
Liquidation preference of $0 as of September 30, 2026.
   -    1,551,232 
Redeemable Series I Convertible Preferred Stock, ($0.0001 par value per share and $1,000 face value per share; authorized - 7,000 shares; issued and outstanding – 300 and 7,000 shares, at September 30, 2026 and December 31, 2025, respectively).
Liquidation preference of $434,728 as of September 30, 2026.
   423,200    4,451,040 
Redeemable Series K Convertible Preferred Stock, ($0.0001 par value per share and $1,000 face value per share; authorized - 21,500 shares; issued and outstanding - 19,247 and 0 shares, at September 30, 2026 and December 31, 2025, respectively).
Liquidation preference of $19,720,366 as of September 30, 2026.
   10,187,621    — 
Redeemable Series J Convertible Preferred Stock, ($0.0001 par value per share and $1,000 face value per share; authorized - 3,810 shares; issued and outstanding - 3,397 and 0 shares, at September 30, 2026 and December 31, 2025, respectively).
Liquidation preference of $4,355,570 as of September 30, 2026.
   6,165,160    — 
           
Stockholders’ equity:          
Preferred Stock, (authorized – 20,000,000 shares)   —    — 
Series H Convertible Preferred Stock, ($0.0001 par value per share; authorized – 8,500 shares; issued and outstanding – 8 shares as of September 30, 2026 and December 31, 2025, respectively)
Liquidation preference of $0 as of September 30, 2026.
   —    — 
Convertible Preferred Stock Series H-3, ($0.0001 par value; authorized – 8,461 shares; issued and outstanding – 1,234 shares as of September 30, 2026 and December 31, 2025, respectively)
Liquidation preference of $18 as of September 30, 2026.
   —    — 
Series H-6 Convertible Preferred Stock, ($0.0001 par value per share; authorized – 50,000 shares; issued and outstanding – 50 shares as of September 30, 2026 and December 31, 2025, respectively)
Liquidation preference of $89 as of September 30, 2026.
   —    — 
Common Stock, ($0.0001 par value; authorized – 1,200,000,000 and 200,000,000 shares as of September 30, 2026, and December 31, 2025, respectively; issued and outstanding – 7,456,987 and 1,455,975 shares as of September 30, 2026, and December 31, 2025, respectively)   746    146 
Additional paid-in capital   165,203,414    141,884,878 
Accumulated deficit   (157,978,673)   (138,174,663)
Total stockholders’ equity   7,225,487    3,710,361 
Total liabilities, mezzanine equity and stockholders’ equity  $39,179,567   $11,408,652 

 

See the accompanying notes to these unaudited condensed consolidated financial statements

 

F-2

 

 

FABRIC.AI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Revenue  $—   $—   $—   $— 
Cost of goods sold   —    717,120    —    956,160 
Gross loss   —    (717,120)   —    (956,160)
                     
Operating expenses:                    
Research and development   9,352,874    343,556    10,167,630    1,001,237 
General and administrative   3,156,979    2,472,964    7,372,354    5,338,109 
Total operating expenses   12,509,853    2,816,520    17,539,984    6,339,346 
                     
Loss from operations   (12,509,853)   (3,533,640)   (17,539,984)   (7,295,506)
                     
Other income (expense):                    
Interest income   62,025    61,956    102,620    96,157 
Change in fair value - warrant liability   —    547,000    —    (11,627,100)
Change in fair value - derivative liability   —    179,000    37,000    2,840,000 
Change in fair value - anti-dilution liability   7,412,199    —    (632,135)   — 
Unrealized gain (loss) on marketable securities   36,315    (37,119)   90,274    (116,283)
Change in fair value of digital assets   —    (228,972)   (538,609)   (228,972)
Realized gain on marketable securities   91,811    82,345    155,911    387,899 
Consent and waiver fee - Series H-7   —    —    —    (350,000)
Gain on sale of assets   —    —    218,803    — 
Other income (expense), net   —    171,192    (1,697,889)   237,560 
Total other income (expense), net   7,602,350    775,402    (2,264,025)   (8,760,739)
                     
Net income (loss) prior to provision for income taxes  $(4,907,503)  $(2,758,238)  $(19,804,009)  $(16,056,245)
                     
Provision for income taxes   —    —    —    — 
                     
Net loss  $(4,907,503)  $(2,758,238)  $(19,804,009)  $(16,056,245)
                     
Dividends earned on convertible preferred stock   (423,186)   (132,872)   (943,769)   (1,837,066)
Accretion of discounts to redemption value of Series I and Series H-7 convertible preferred stock   —    (739,733)   (2,689,931)   (3,988,634)
                     
Net loss attributable to common stockholders  $(5,330,689

)

  $(3,630,843)  $(23,437,709)  $(21,881,945)
                     
Net loss per share basic  $(0.75)  $(3.84)  $(5.51)  $(16.18)
Net loss per share diluted  $(0.75)  $(3.84)  $(5.51)  $(16.18)
                     
Basic weighted average Common Stock outstanding   7,096,529    946,139    4,251,365    1,352,078 
Diluted weighted average Common Stock outstanding   7,096,529    946,139    4,251,365    1,352,078 

 

See the accompanying notes to these unaudited condensed consolidated financial statements

 

F-3

 

 

FABRIC.AI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   (Deficit)   Total 
   Three and Nine Months Ended September 30, 2026 
   Series K   Series J   Series I   Series H-7   Series H   Series H-3   Series H-6           Additional         
   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Common Stock   Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   (Deficit)   Total 
Balance, January 1, 2026   —   $—    —   $—    7,000   $4,451,040    1,180   $1,551,232    8   $—    1,234   $—    50   $—    1,455,975   $146   $141,884,878   $(138,174,663)  $3,710,361 
Deemed dividend   —    —    —    —    —    (252,509)   —    (151,024)   —    —    —    —    —    —    —    —    —    —    — 
Preferred stock dividends   —    —    —    —    —    190,987    —    (24,316)   —    —    —    —    —    —    —    —    (166,671)   —    (166,671)
Accretion of discounts to redemption value of Series I convertible preferred stock   —    —    —    —    —    941,478    —    —    —    —    —    —    —    —    —    —    (941,478)   —    (941,478)
Issuance of consultant warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    992,576    —    992,576 
Net income   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (2,414,475)   (2,414,475)
Balance, March 31, 2026   —   $—    —   $—    7,000   $5,330,996    1,180   $1,375,892    8   $—    1,234   $—    50   $—    1,455,975   $146   $141,769,305   $(140,589,138)  $1,180,313 
Stock-based compensation   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    848,546    —    848,546 
Issuance of convertible preferred stock, net of discounts and transaction costs   21,500    10,851,482    3,810    5,606,454    —    —    —    —    —    —    —    —    —    —    —    —    8,864,064    —    8,864,064 
Preferred stock redemptions and conversions including cash premium   —    —    —    —    (6,700)   (6,442,529)   (1,180)   (1,389,654)   —    —    —    —    —    —    3,204,291    320    7,831,862    —    7,832,182 
Preferred stock dividends   —    259,194    —    29,566    —    49,913    —    15,241    —    —    —    —    —    —    —    —    (353,912)   —    (353,912)
Accretion of discounts to redemption value of Series I convertible preferred stock   —    —    —    —    —    1,748,453    —    —    —    —    —    —    —    —    —    —    (1,748,453)   —    (1,748,453)
Common stock issued for exercise of Series H-7 Preferred warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    1,180,000    118    2,961,800    —    2,961,918 
Common stock issued for exercise of Series I Preferred warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    823,646    82    2,067,269    —    2,067,351 
Amendment modification   —    —    —    —    —    (269,000)   —    (1,479)   —    —    —    —    —    —    —    —    163,479    —    163,479 
Warrant modification   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (838,462)   —    (838,462)
Issuance of Series H-7 and Series I waiver warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    1,565,000    —    1,565,000 
Issuance of consultant warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    1,105,781    —    1,105,781 
Net loss   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (12,482,032)   (12,482,032)
Balance, June 30, 2026   21,500   $11,110,676    3,810   $5,636,020    300   $417,833    —   $—    8   $—    1,234   $—    50   $—    6,663,912   $666   $164,236,279   $(153,071,170)  $11,165,775 
Stock-based compensation   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    966,491    —    966,491 
Common stock issued for exercise of Series H-7 Preferred warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    30,000    3    75,297    —    75,300 
Issuance of convertible preferred stock, net of discounts and transaction costs   —    —    450    468,164    —    —    —    —    —    —    —    —    —    —    —    —    —    —    — 
Preferred stock redemptions and conversions including cash premium   (2,253)   (1,137,040)   —    —    —    —    —    —    —    —    —    —    —    —    897,535    90    1,136,950    —    1,137,040 
Repurchase of RSUs   —    —    —    —    —    —    —    —    —    —    —    —    —    —    (134,460)   (13)   (380,060)   —    (380,073)
Warrant issuance costs   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (408,357)        (408,357)
Deemed dividend   —    (142,858)   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    — 
Preferred stock dividends   —    356,843    —    60,976    —    5,367    —    —    —    —    —    —    —    —    —    —    (423,186)   —    (423,186)
Net loss   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (4,907,503)   (4,907,503)
Balance, September 30, 2026   19,247   $10,187,621    4,260   $6,165,160    300   $423,200    —   $—    8   $—    1,234   $—    50   $—    7,456,987   $746   $165,203,414   $(157,978,673)  $7,225,487 

 

                   Three and Nine Months Ended September 30, 2025 
   Series K   Series J   Series I   Series H-7   Series H   Series H-3   Series H-6           Additional         
   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Preferred Stock   Common Stock   Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   (Deficit)   Total 
Balance, January 1, 2025   —   $—    —   $—    —   $—    10,167   $7,587,518    8   $—    1,234   $—    50   $—    533,842   $53   $121,767,394   $(117,085,518)  $4,681,929 
Preferred stock redemptions and conversions including cash premium   —    —    —    —    —    —    (5,500)   (6,404,587)   —    —    —    —    —    —    —    —    —    —    — 
Deemed dividend   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (338,915)   —    (338,915)
Preferred stock dividends   —    —    —    —    —    —    —    494,818    —    —    —    —    —    —    —    —    (494,818)   —    (494,818)
Accretion of discounts to redemption value of Series H-7 convertible preferred stock   —    —    —    —    —    —    —    1,686,854    —    —    —    —    —    —    —    —    (1,686,854)   —    (1,686,854)
Net income   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    845,011    845,011 
Balance, March 31, 2025   —   $—    —   $—    —   $—    4,667   $3,364,603    8   $—    1,234   $—    50   $—    533,842   $53   $119,246,807   $(116,240,507)  $3,006,353 
Stock based compensation   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    69,480    —    69,480 
Preferred stock redemptions and conversion including cash premium   —    —    —    —    —    —    (4,667)   (5,473,475)   —    —    —    —    —    —    56,215    6    394,609    —    394,615 
Deemed dividend   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (323,636)   —    (323,636)
Preferred stock dividends   —    —    —    —    —    —    —    546,825    —    —    —    —    —    —    —    —    (546,825)   —    (546,825)
Accretion of discounts to redemption value of Series H-7 convertible preferred stock   —    —    —    —    —    —    —    1,562,047    —    —    —    —    —    —    —    —    (1,562,047)   —    (1,562,047)
Issuance of round up shares   —    —    —    —    —    —    —    —    —    —    —    —    —    —    124    —    —    —    — 
Net loss   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (14,143,018)   (14,143,018)
Balance, June 30, 2025   —   $—    —   $—    —   $—    —   $—    8   $—    1,234   $—    50   $—    590,181   $59   $117,278,388   $(130,383,525)  $(13,105,078)
Issuance of convertible preferred stock, net of discounts and transaction costs   —    —    —    —    7,000    2,427,112    4,377    5,269,500    —    —    —    —    —    —    —    —    (87,016)   —    (87,016)
Common stock issued for exercise of Series H-7 Preferred warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    178,200    18    1,103,630         1,103,648 
Issuance of consultant warrants   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    1,680,293    —    1,680,293 
Preferred stock redemption and conversions including cash premium   —    —    —    —    —    —    (1,113)   (3,220,348)   —    —    —    —    —    —    587,594    59    3,759,262    —    3,759,321 
Accretion of discounts to redemption value of Series H-7 convertible preferred stock   —    —    —    —    —    739,733    —    —    —    —    —    —    —    —    —    —    (739,733)   —    (739,733)
Reclassification of warrant liability to equity   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    18,608,000    —    18,608,000 
Deemed dividend   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    26,949    —    26,949 
Preferred stock dividends   —    —    —    —    —    53,472    —    70,095    —    —    —    —    —    —    —    —    (159,821)   —    (159,821)
Net income   —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    —    (2,758,238)   (2,758,238)
Balance, September 30, 2025   —   $—    —   $—    7,000   $3,220,317    3,264   $2,119,247    8   $—    1,234   $—    50   $—    1,355,975   $136   $141,469,952   $(133,141,763)  $8,328,325 

 

See the accompanying notes to these unaudited condensed consolidated financial statements

 

F-4

 

 

FABRIC.AI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(19,804,009)  $(16,056,245)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   —    20,109 
Stock-based compensation   3,401,253    477,126 
Series H-7 preferred stock waiver   —    350,000 
Series I financing costs   —    754,815 
Non-cash financing expense related to Series H-7 and Series I convertible preferred stock   1,565,000    — 
Gain on sale of assets   (218,803)   — 
Change in fair value - derivative liability   (37,000)   (2,840,000)
Change in fair value - warrant liability   —    11,627,100 
Change in fair value - anti-dilution liability   632,135    — 
Amortization of right-of-use asset   131,656    149,831 
Change in fair value of digital assets   538,609    228,972 
Unrealized (gain)/loss on marketable securities   (90,274)   116,283 
Realized gain on marketable securities   (155,911)   (387,899)
Change in operating assets and liabilities:          
Prepaid expenses and other current assets   101,349    660,622 
Deposits and other assets   20,883    501 
Accounts payable   457,665    (750,213)
Accounts payable - related party   (28,533)   — 
Accrued expenses and other current liabilities   1,115,833    (234,771)
Lease obligations - operating leases   (185,125)   (161,868)
Net cash used in operating activities   (12,555,272)   (6,045,637)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Proceeds from sale of marketable securities, net   14,957,142    28,281,311 
Proceeds from sale of digital assets   1,410,390    — 
Purchase of marketable securities   (25,390,243)   (28,801,651)
Purchase of digital assets   0    (1,800,000)
Investment in Kopin license rights   (128,521)   — 
Net cash used in investing activities   (9,151,232)   (2,320,340)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from sale of preferred stock (K), net of transaction costs   19,720,000    — 
Proceeds from sale of preferred stock (I), net of transaction costs   —    6,314,297 
Proceeds from exercise of Series H-7 and Series I preferred warrants   5,104,569    1,103,648 
Payment of warrant issuance costs   (408,357)   — 
Payment of preferred stock dividends (Series H-7, Series I and Series K)   (546,389)   (7,881,527)
Net cash provided by (used in) financing activities   23,869,823    (463,582)
           
Net change in cash, cash equivalents and restricted cash   2,163,319    (8,829,559)
Cash, cash equivalents and restricted cash, beginning of period   5,092,062    16,200,157 
Cash, cash equivalents and restricted cash, end of period  $7,255,381   $7,370,598 
           
Supplemental disclosure of cash and non-cash transactions:          
Common stock issued for cashless conversion of Series H-7, Series I and Series K convertible preferred stock  $8,969,222    — 
Accrual of Series H-7 convertible preferred stock dividends  $9,075   $1,646,758 
Accrual of Series I convertible preferred stock dividends  $246,267   $53,472 
Accrual of Series J convertible preferred stock dividends  $90,542    — 
Accrual of Series K convertible preferred stock dividends  $616,037    — 
Accretion of discounts to redemption value of I convertible preferred stock  $2,689,931   $3,988,634 
Deemed dividend Series H-7, Series I, Series warrants  $—   $662,551 
Accretion of discounts to redemption value of H-7 convertible preferred stock  $—   $5,457,504 
Accrued Series H-7 preferred stock redemption payable  $—   $11,878,064 
Non-cash redemption of Series H-7 preferred stock  $—   $4,153,935 
Reclassification of warrant liability to equity (Series H-7)  $—   $13,891,000 
Reclassification of warrant liability to equity (Series I)  $—   $4,080,034 
Accrued waiver fee related to Series H-7 preferred stock  $—   $350,000 
Prepaid insurance financed through accrued expenses  $—   $110,208 
           
Supplemental disclosure of restricted cash:          
Cash and cash equivalents  $2,152,690   $7,260,657 
Restricted cash   5,102,691    109,941 
Total cash, cash equivalents and restricted cash  $7,255,381   $7,370,598 

 

See the accompanying notes to these unaudited condensed consolidated financial statements

 

F-5

 

 

FABRIC.AI, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS

 

Organization

 

Fabric.AI, Inc. (“Fabric.AI” or the “Company”) is a Delaware corporation headquartered in New York, New York. The Company operates through its wholly-owned subsidiary, AYRO Operating Company, Inc. (“AYRO Operating”).

 

On April 27, 2026, the Company amended its Amended and Restated Certificate of Incorporation to change its name from “StableX Technologies, Inc.” to “Fabric.AI, Inc.” effective April 28, 2026. The ticker symbol for the Company’s common stock, par value $0.0001 per share (“common stock”), changed from “SBLX” to “FABC” and began trading under the new symbol on The Nasdaq Capital Market on April 29, 2026.

 

Nature of Operations

 

During the nine months ended September 30, 2026, the Company initiated a strategic transformation focused on the design and development of fabless semiconductor technologies for artificial intelligence (“AI”) data center infrastructure, including MicroLED-based optical interconnects and other system-critical semiconductor solutions intended to enable faster, more efficient and scalable AI workloads.

 

On April 27, 2026, the Company entered into a Joint Development and License Agreement (“JDA”) and related commercial agreements with Kopin Corporation, a Delaware corporation (“Kopin”) (Nasdaq: KOPN) to jointly develop and commercialize MicroLED-based optical interconnect technologies and related semiconductor products. For additional information, see Note 16. Commitments and Contingencies.

 

The Company’s initial product under development is the Neural I/o™ chip, a micro light-emitting diode (“MicroLED”) based optical interconnect being developed in collaboration with Kopin Corporation, pursuant to the JDA. The Neural I/o chip is intended to replace traditional electrical interconnects with optical links to enable high-bandwidth, low-latency communication between compute nodes, with an initial focus on GPU-to-GPU connectivity for AI data center applications.

 

The collaboration with Kopin combines the Company’s system-level design capabilities with Kopin’s expertise in MicroLED materials science, process development and fabrication. The Neural I/oTM chip leverages Kopin’s proprietary MicroLED technology and patented bi-directional NeuralDisplay architecture, which repurposes programmable MicroLED pixels as optical transceivers intended to transmit data with lower power consumption relative to existing copper-based and laser-based interconnect solutions. The parties have agreed to jointly develop prototype and demonstration versions of the technology in accordance with the development plans established under the JDA. Intellectual property developed through the collaboration will be jointly owned by the Company and Kopin, while Kopin retains ownership of its pre-existing technology and has granted the Company commercialization rights for commercial market applications.

 

The Company’s semiconductor initiatives are in the early stages of development. The extent to which the Company advances its semiconductor technologies and related activities will depend on factors including available capital, market conditions, regulatory developments, technical progress, manufacturing feasibility and customer adoption within the AI infrastructure industry. As of the date of this filing, the Company had approximately $6.5 million in cash and cash equivalents and $13.6 million in marketable securities available to support its strategic transition and ongoing development activities.

 

During 2025, the Company had initiated a digital asset treasury strategy associated with the stablecoin ecosystem. During the nine months ended September 30, 2026, the Company disposed of all its digital asset holdings and does not intend to develop this strategy further (see Note 7. Digital Assets).

 

During the year ended December 31, 2025, the Company paused active development and commercialization activities related to its electric vehicle business while it evaluates strategic alternatives for that business line. During the nine months ended September 30, 2026, the Company sold its assets associated with electric vehicle operations (see Note 15. Sale of Legacy Electric Vehicle Assets).

 

F-6

 

 

NOTE 2. LIQUIDITY AND GOING CONCERN

 

The unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”), which contemplates continuation of the Company as a going concern. The Company is subject to a number of risks similar to those of earlier stage commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies, and other technologies. The Company has a limited operating history and the sales and income potential of its business and market are unproven.

 

During the nine months ended September 30, 2026, the Company completed equity financing transactions that generated approximately $21.5 million in gross proceeds (see Note 8. Stockholders’ Equity for additional information regarding these financing transactions). As of the date of this filing, the Company had approximately $6,473,000 in cash and cash equivalents and $13,575,000 in marketable securities. Based on the Company’s current cash position and management’s operating plan, management believes the Company has sufficient liquidity to fund operations for at least the next twelve months from the issuance date of these unaudited condensed consolidated financial statements.

 

Management evaluated whether conditions and events raised substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date these unaudited condensed consolidated financial statements are issued. Although the Company’s recurring operating losses and negative operating cash flows initially raised substantial doubt about its ability to continue as a going concern, management concluded that such substantial doubt has been alleviated as a result of the capital raised during the nine months ended September 30, 2026, and the Company’s current operating plan. Accordingly, management believes the Company has sufficient liquidity to fund its operations for at least the next twelve months from the issuance date of these unaudited condensed consolidated financial statements. However, the Company may require additional capital in the future to support the continued development and commercialization of its business, including its semiconductor development initiatives, and there can be no assurance that such financing will be available on acceptable terms, if at all.

 

The Company incurred a net loss of $19,804,009 and cash used in operating activities of $12,555,272 for the nine months ended September 30, 2026. In addition, overall working capital increased by $10,860,598 during the nine months ended September 30, 2026, primarily as a result of the financing transactions completed during the second quarter.

 

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Our significant accounting policies are described in Note 3 to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The following policies are new to the Company during the nine months ended September 30, 2026, or have been updated to reflect changes in the current period.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which are, in the opinion of management, necessary for a fair presentation of such statements. The results of operations for the three and nine months ended September 30, 2026, are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the fiscal year ended December 31, 2025, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 30, 2026.

 

Use of Estimates

 

The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of and during the reported period of the condensed consolidated financial statements. Actual results could differ from those estimates. The Company evaluates estimates and assumptions on an ongoing basis.

 

F-7

 

 

Intangible Assets

 

Intangible assets acquired individually or as part of a group of assets are recorded at cost, which for noncash consideration is measured at the fair value of the consideration transferred on the acquisition date. The Company’s intangible assets consist of an acquired license right that has been determined to have an indefinite useful life. Indefinite-lived intangible assets are not amortized.

 

The Company evaluates its indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support an indefinite useful life. Indefinite-lived intangible assets are tested for impairment at least annually, and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.

 

Anti-Dilution Liability

 

In connection with the issuance of the Series J Convertible Preferred Stock, the Company identified anti-dilution provisions that represent a freestanding financial instrument. Because the instrument does not qualify for equity classification, the Company records it as a liability, initially measured at its issuance-date fair value.

 

The anti-dilution liability is subsequently remeasured at a fair value on a recurring basis at each reporting date, with changes in fair value recognized in other income (expense), net in the condensed consolidated statements of operations. The fair value is determined using significant unobservable inputs and is classified within Level 3 of the fair value hierarchy. when the Company settles its obligation under the anti-dilution provisions by issuing additional shares of Series J Preferred Stock, the carrying amount of the liability is reduced, with a corresponding increase to temporary equity.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization included in each relevant expense caption presented on the statement of operations. The standard also requires disclosure of qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as the total amount of selling expenses and an entity’s definition of selling expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact this standard will have on its financial statements.

 

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to its financial statements.

 

NOTE 4. BASIC AND DILUTED NET LOSS PER SHARE

 

Due to the Company incurring a net loss for the three and nine months ended September 30, 2026 and 2025, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as their inclusion would have been anti-dilutive:

 

   2026   2025 
   Three Months Ended September 30, 
   2026   2025 
Options to purchase Common Stock   1,647,005    14,542 
Restricted stock units   178,309    - 
Warrants outstanding   20,729,851    6,275,103 
Preferred stock outstanding   9,751,164    47 
Totals   32,306,329    6,289,692 

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Options to purchase Common Stock   789,522    14,542 
Restricted stock units   72,567    - 
Warrants outstanding   14,323,280    9,036,597 
Preferred stock outstanding   6,577,126    47 
Totals   21,762,494    9,051,186 

 

NOTE 5. INVESTMENTS IN MARKETABLE SECURITIES

 

The Company’s investments consist of (i) U.S. Treasury bills and (ii) investments in a prime institutional money market fund. These investments are measured at fair value with changes in fair value recognized in earnings within Other income (expense), net in the unaudited condensed consolidated statements of operations.

 

F-8

 

 

The Company classifies investments with original maturities of three months or less at the date of purchase as cash and cash equivalents and those with original maturities greater than three months as marketable securities.

 

Trading debt securities: the Company’s U.S. Treasury bills are classified as trading debt securities. Realized and unrealized gains and losses are recognized in earnings.

 

Money market fund: the Company also invests in a prime institutional money market fund, which is a pooled investment vehicle that invests in a diversified portfolio of short-term, high-quality debt instruments, including U.S. government securities, commercial paper, certificates of deposit, and repurchase agreements. The investment is recorded at fair value and changes in fair value are recognized in earnings.

 

The following table summarizes the Company’s trading securities by major investment type as of September 30, 2026 and December 31, 2025:

 

   September 30,   December 31, 
Security Type:  2026   2025 
U.S. Treasury Bills  $12,884,850   $2,718,112 
Prime institutional money market fund   962,798    450,250 
Total Trading Securities  $13,847,648   $3,168,362 

 

The Company recognized an unrealized gain of $36,315 and $90,274 for the three and nine months ended September 30, 2026, and an unrealized loss of $37,119 and $116,283 for the three and nine months ended September 30, 2025. The Company recognized realized gains of $91,811 and $82,345 for the three months ended September 30, 2026 and 2025, respectively, and $155,911 and $387,899 for the nine months ended September 30, 2026 and 2025, respectively.

 

NOTE 6. INTANGIBLE ASSETS

 

During the nine months ended September 30, 2026, in connection with the JDA, see Note 16. Commitments and Contingencies, the Company recognized an intangible asset of $17,238,716 representing the fair value of its license to use Kopin’s technology in the Company’s fabless semiconductor (the “License”). The fair value of the License was determined based on the fair value of the consideration transferred to Kopin, comprising the $730,533 initial fair value of the Series J Convertible Preferred Stock issued to Kopin (see Note 8. Stockholders’ Equity) and the $16,379,662 initial fair value of the associated anti-dilution liability (see Note 11. Fair Value Measurements), together with $128,521 of direct transaction costs incurred in connection with the transaction.

 

The License provides the core technology used in the Company’s fabless semiconductor operations, and the Company expects its future revenue to be generated from the sale of semiconductors manufactured using that technology. In determining the useful life of the License, management analyzed all pertinent factors, including the terms of the underlying agreements and management’s intent and ability to continue the arrangement. As of September 30, 2026, management expects to extend the arrangement beyond its initial term and considers the probability of non-renewal or termination to be remote. Because the License is expected to contribute to the Company’s cash flows without a foreseeable limit, management concluded that the License has an indefinite useful life. Accordingly, the License is not amortized.

 

The Company reassesses each reporting period whether events and circumstances continue to support an indefinite useful life. The License is tested for impairment at least annually, and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. An impairment loss is recognized to the extent the carrying amount of the License exceeds its fair value. No impairment was recognized during the three and nine months ended September 30, 2026.

 

Intangible assets consisted of the following at September 30, 2026:

 

   Gross carrying amount 
License right  $17,238,716 

 

NOTE 7. DIGITAL ASSETS

 

The following table presents a reconciliation of the Company’s digital asset activity for the nine months ended September 30, 2026:

 

   As of September 30, 2026 
Beginning balance at January 1, 2026  $1,948,999 
Change in fair value   (538,609)
Sale of digital assets   (1,410,390)
Ending balance at September 30, 2026  $— 

 

During the three and nine months ended September 30, 2026, the Company recognized losses on change in fair value of digital assets of $0 and $538,609, respectively.

 

During the nine months ended September 30, 2026, the Company disposed of all of its digital assets.

 

NOTE 8. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

Series H Convertible Preferred Stock

 

On June 30, 2015, the Company filed the Certificate of Designations, Preferences and Rights of the Series H Preferred Stock (the “Series H Certificate of Designation”) with the Secretary of State of Delaware, establishing and designating the rights, powers and preferences of the Series H Preferred Stock. Under the terms of the Series H Certificate of Designation, each share of the Company’s Series H Convertible Preferred Stock (the “Series H Preferred Stock”) has a stated value of $154.00 and is convertible into shares of the Company’s common stock, equal to the stated value divided by the conversion price of $23,654.10 per share (subject to adjustment in the event of stock splits or dividends). The Company is prohibited from effecting the conversion of the Series H Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially own more than 9.99%, in the aggregate, of the issued and outstanding shares of the Company’s common stock calculated immediately after giving effect to the issuance of shares of common stock upon such conversion.

 

In the event of liquidation, the holders of the Series H Preferred Stock are entitled, pari passu with the holders of common stock, to receive a payment in the amount the holder would receive if such holder converted the Series H Preferred Stock into common stock immediately prior to the date of such payment.

 

F-9

 

 

Series H-3 Convertible Preferred Stock

 

On March 30, 2017, the Company filed the Certificate of Designation, Preferences and Rights of the Series H-3 Preferred Stock (the “Series H-3 Certificate of Designation”) with the Secretary of State of the State of Delaware, establishing and designating the rights, powers and preferences of the Series H-3 Preferred Stock. Under the terms of the Series H-3 Certificate of Designation, each share of the Series H-3 Preferred Stock has a stated value of $138.00 and is convertible into shares of common stock, equal to the stated value divided by the conversion price of $21,196.60 per share (subject to adjustment in the event of stock splits and dividends). The Company is prohibited from effecting the conversion of the Series H-3 Preferred Stock to the extent that, as a result of such conversion, the holder or any of its affiliates would beneficially own more than 9.99%, in the aggregate, of the issued and outstanding shares of common stock calculated immediately after giving effect to the issuance of shares of common stock upon the conversion of the Series H-3 Preferred Stock.

 

In the event of liquidation, the holders of the Series H-3 Preferred Stock are entitled, pari passu with the holders of common stock, to receive a payment in the amount the holder would receive if such holder converted the Series H-3 Preferred Stock into common stock immediately prior to the date of such payment.

 

Series H-6 Convertible Preferred Stock

 

On February 5, 2020, the Company filed the Certificate of Designations, Preferences and Rights of the Series H-6 Preferred Stock (the “Series H-6 Certificate of Designation”) with the Secretary of State of the State of Delaware, establishing and designating the rights, powers and preferences of the Series H-6 Preferred Stock. The Company designated up to 50,000 shares of Series H-6 Preferred Stock and each share has a stated value of $72.00 (the “H-6 Stated Value”). Each share of Series H-6 Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock of the Company determined by dividing the H-6 Stated Value by the initial conversion price of $460.80 per share, which was then further reduced to $320.00 under the anti-dilution adjustment provision, subject to a 9.99% blocker provision and further reduced to $92.16 under the anti-dilution adjustment provision. The Series H-6 Preferred Stock has the same dividend rights as the common stock, except as provided for in the Series H-6 Certificate of Designation or as otherwise required by law. The Series H-6 Preferred Stock also has the same voting rights as the common stock, except that in no event shall a holder of Series H-6 Preferred Stock be permitted to exercise a greater number of votes than such holder would have been entitled to cast if the Series H-6 Preferred Stock had immediately been converted into shares of common stock at a conversion price equal to $92.16. In addition, a holder (together with its affiliates) may not be permitted to vote Series H-6 Preferred Stock held by such holder to the extent that such holder would beneficially own more than 9.99% of the Company common stock. In the event of any liquidation or dissolution, the Series H-6 Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution.

 

The holders of Series H-6 Preferred Stock are entitled to certain anti-dilution adjustments if the Company issues shares of its common stock at a lower price per share than the applicable conversion price of the Series H-6 Preferred Stock. If any such dilutive issuance occurs prior to the conversion of the Series H-6 Preferred Stock, the conversion price will be adjusted downward to a price that cannot be less than $92.16.

 

Series H-7 Preferred Stock

 

On August 7, 2023, the Company entered into a Securities Purchase Agreement (the “Series H-7 Purchase Agreement”), pursuant to which it agreed to sell to certain existing investors (the “Series H-7 Investors”) in a private placement (the “Series H-7 Private Placement”) (i) an aggregate of 22,000 shares of the Company’s newly designated Series H-7 convertible preferred stock, par value $0.0001 per share, with a stated value of $1,000 per share (“Series H-7 Preferred Stock”), and (ii) warrants (the “Series H-7 Investor Warrants”) initially exercisable for up to an aggregate of 171,875 shares of common stock at a conversion price of $128.00 per share. The Company raised gross proceeds of $22,000,000 from the sale, which closed on August 10, 2023.

 

F-10

 

  

During the nine months ended September 30, 2026, the holders converted the remaining 1,180 shares of Series H-7 Preferred Stock for an aggregate amount of 534,975 shares of common stock. As a result, there were no outstanding shares of Series H-7 Preferred Stock at September 30, 2026.

 

During the three and nine months ended September 30, 2026, the Company recognized $- and $160,099 of net preferred dividends which is comprised of $151,024 and $9,075 of accrued and deemed preferred dividends for cash premium on instalment redemptions ultimately settled in shares of Common Stock.

 

During the three and nine months ended September 30, 2025, the Company recognized $227,727 and $1,931,921 of net preferred dividends which is comprised of $106,349 and $1,147,992, respectively, of preferred dividends at the stated dividend rate recorded in mezzanine equity, and $121,377 and $783,929, respectively, of accrued and deemed dividends recorded in stockholders’ equity for cash premium for instalment redemptions ultimately settled in shares of Common Stock.

 

Series I Preferred Stock

 

On August 4, 2025, the Company entered into a Securities Purchase Agreement (the “Series I Purchase Agreement”) with certain accredited investors, pursuant to which it agreed to sell (i) an aggregate of 7,000 shares of the Company’s newly-designated Series I Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 875,000 shares of the Company’s common stock at an initial conversion price of $8.00 per share pursuant to the Certificate of Designations of the Series I Preferred Stock (the “Series I Certificate of Designations”) and (ii) warrants to acquire up to an aggregate of 875,000 shares of common stock (the “Series I Warrants”) at an exercise price of $8.00 per share (collectively, the “Series I Private Placement”). The closing of the Series I Private Placement occurred on August 8, 2025. The aggregate gross proceeds from the Series I Private Placement were $7,000,000.

 

In connection with the Series I Private Placement, pursuant to (A) an engagement letter (the “GPN Agreement”) with GP Nurmenkari Inc. (“GPN”) and (B) an engagement letter (the “Palladium Agreement,” and collectively with the GPN Agreement, the “Engagement Letters”) with Palladium Capital Group, LLC (“Palladium,” and collectively with GPN, the “Placement Agents”), the Company engaged the Placement Agents to act as non-exclusive placement agents in connection with the Series I Private Placement, pursuant to which, the Company agreed to (i) pay each Placement Agent a cash fee equal to 4% of the gross proceeds of the Series I Private Placement (including any cash proceeds realized by the Company from the exercise of any outstanding warrants of the Company), (ii) reimbursement and payment of certain expenses, and (iii) issue to each of the Placement Agents on the closing date, warrants to purchase up to an aggregate number of shares of common stock equal to 4% of the aggregate number of shares of common stock underlying the securities issued in the Series I Private Placement, including upon exercise of any outstanding warrants of the Company, with terms identical to the Series I Warrants (the “Series I Placement Agent Warrants”).

 

The Series I Preferred Stock is convertible into shares of common stock (the “Series I Conversion Shares”) at the election of the holder at any time at an initial conversion price of $8.00 per share (the “Series I Conversion Price”). The Series I Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like and dilutive issuances (in each case, subject to certain exceptions). Prior to the April 2026 Series I Amendment, the Company was required to redeem the Series I Preferred Stock in equal installments, commencing on November 30, 2025, and thereafter on the last trading day of the third calendar month immediately following the previous Installment Date. The maturity date is October 27, 2027.

 

F-11

 

 

The holders of the Series I Preferred Stock are entitled to dividends of 7% per annum, compounded each calendar quarter, which are payable in arrears (i) quarterly on each Installment Date (as defined in the Series I Certificate of Designations), in cash out of funds legally available therefor and, (ii) prior to the first Installment Date, payable by way of inclusion of the dividends in the Conversion Amount (as defined in the Series I Certificate of Designations) on each conversion date occurring prior to the first Installment Date. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Series I Certificate of Designations), the Series I Preferred Stock accrue dividends at the rate of 15% per annum. The holders of the Series I Preferred Stock are entitled to vote with holders of the Common Stock on an as-converted basis, with the number of votes to which each holder of Series I Preferred Stock is entitled to be calculated assuming a conversion price of $7.628 per share, which was the Minimum Price (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) applicable immediately before the execution and delivery of the Series I Purchase Agreement, subject to certain beneficial ownership limitations as set forth in the Certificate of Designations.

 

Notwithstanding the foregoing, the Company’s ability to settle conversions using shares of common stock is subject to certain limitations set forth in the Series I Certificate of Designations. Further, the Series I Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of common stock issuable upon conversion of the Series I Preferred Stock under the Series I Certificate of Designations.

 

The Series I Certificate of Designations includes certain triggering events including, among other things, the suspension from trading or the failure of the common stock to be trading or listed (as applicable) on an eligible market for a period of five (5) consecutive trading days, the Company’s failure to pay any amounts due to the holders of the Series I Preferred Stock when due. In connection with a triggering event, each holder of Series I Preferred Stock will be able to require the Company to redeem in cash any or all of the holder’s shares of Series I Preferred Stock at a premium set forth in the Series I Certificate of Designations.

 

The shares of Series I Preferred Stock were determined to be more akin to a debt-like host than an equity-like host. The Company identified the following embedded features that are not clearly and closely related to the debt host instrument: 1) make-whole interest upon a contingent redemption event, 2) make-whole interest upon a conversion event and 3) an increase in the dividend rate related to the occurrence of a triggering event. These features were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these features are recognized in the unaudited condensed consolidated statement of operations. The Company estimated the $23,000 fair value of the bifurcated embedded derivative at issuance using a Monte Carlo simulation model, with the following inputs: (i) estimated equity volatility of 135.0%, (ii) the time to maturity of 1.49 years, (iii) a discounted market interest rate of 13.76%, (iv) dividend rate of 7.0%, (v) a penalty dividend rate of 15.0%, and (vi) probability of default of 9%. The fair value of the bifurcated derivative liability was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla maturity scenario without a derivative.

 

On April 27, 2026, the Company entered into an Omnibus Waiver, Consent, Notice and Amendment (the “April 2026 Series I Amendment,” and together with the April 2026 Series H-7 Amendment, the “April 2026 Amendment”) with the Required Holders, pursuant to which the Company filed an amended and restated Certificate of Designations of the Series I Preferred Stock that (i) extended the maturity date to October 27, 2027, and (ii) removed the installment (amortization) payment obligations and related covenants. In consideration of the foregoing, the Company issued the Waiver Warrants described below.

 

The Company determined that the April 2026 Series I Amendment should also be accounted for as an extinguishment of the original Series I Preferred Stock and a reissuance of the amended instrument as a new instrument on April 27, 2026. Immediately prior to the extinguishment, the carrying value of the Series I Preferred Stock was adjusted to its redemption value, recognizing the related change in fair value of the embedded derivative liability, as discussed in Note 10. Derivative Instruments, through that date. The amended Series I Preferred Stock was then recognized at its reissuance date fair value, with no impact to net income. The Holder’s previously identified option to defer installment payments, which was not separately bifurcated prior to the amendment, is removed with no separate accounting effect.

 

F-12

 

 

The amended Series I Preferred Stock continues to be classified within temporary (mezzanine) equity and considered probable of becoming redeemable, with changes in redemption value continuing to be accreted to the maturity date using the effective interest method.

 

The discount to the fair value is included as a reduction to the carrying value of the Series I Preferred Stock. During the year ended December 31, 2025, the Company recorded a total discount of $10,887,185 upon issuance of the Series I Preferred Stock, which was comprised of the issuance date fair value of the associated embedded derivative of $24,000, stock issuance costs of $1,322,669, of which $567,854 was paid in cash and $754,815 was allocated as the Series I Placement Agent Warrants both of which were recorded to mezzanine equity, and the fair value of the Series I Warrants of $3,981,034. As of September 30, 2026, it is probable that the Series I Preferred Stock will be redeemed. In accordance with ASC 480-10-S99-3A, the Company is accreting the discount on the effective interest method and $2,689,931 was recorded as a deemed dividend during the nine months ended September 30, 2026.

 

In connection with the Series I Purchase Agreement, the Company and the investors entered into a Registration Rights Agreement (the “Series I Registration Rights Agreement”), pursuant to which the Company is required to file a resale registration statement (the “Series I Registration Statement”) with the SEC to register for resale 200% of the shares of common stock issuable upon conversion of the Series I Preferred Stock and upon exercise of the Series I Warrants promptly following the closing date, but in no event later than 30 calendar days after the closing date, and to have such Series I Registration Statement declared effective by the Effectiveness Deadline (as defined in the Series I Registration Rights Agreement). On September 8, 2025, the Company filed the Series I Registration Statement with the SEC and subsequently amended the Series I Registration Statement on October 10, 2025. On January 9, 2026, the SEC declared the Series I Registration Statement effective.

 

As a result of the issuance of the Series K Preferred Stock, as described below, the conversion price was reduced from $8.00 to $2.51 per share.

 

During the nine months ended September 30, 2026, Series I Preferred Stock holders converted 6,700 shares of Series I Preferred Stock for an aggregate amount of 2,669,316 shares of common stock. As a result, there were 300 shares of Series I Preferred Stock outstanding at September 30, 2026.

 

During the three and nine months ended September 30, 2026, the Company recognized $(5,367) and $6,242 of net preferred dividends which is comprised of $252,509 and $(246,267) of accrued and deemed preferred dividends for cash premium on installment redemptions ultimately settled in shares of Common Stock.

 

During the three months ended September 30, 2025, the Company recognized $53,472 of net preferred dividends.

 

Series J Preferred Stock

 

On April 27, 2026, in connection with the JDA, see Note 16. Commitments and Contingencies, the Company issued to Kopin 730 shares of newly designated Series J Convertible Preferred Stock, par value $0.0001 per share and stated value $1,000 per share (the “Series J Preferred Stock”), constituting 19.9% of the pro forma fully diluted outstanding shares of Common Stock, as consideration for Kopin’s grant of the license to the project technology. The Series J Preferred Stock is classified as temporary (mezzanine) equity because it may be settled in cash or other assets upon the occurrence of a Fundamental Transaction (as defined in the Series J Certificate of Designations), which is an event not solely within the Company’s control. Because the shares are not currently redeemable and it is not probable that they will become redeemable (as the Company does not consider the occurrence of a Fundamental Transaction to be probable), the carrying amount is not adjusted to the redemption amount.

 

The Company accounted for the issuance as an asset acquisition under ASC 805. Because the Series J Preferred Stock was issued as non-cash consideration rather than for cash, it was initially measured at its issuance-date fair value of $730,533, determined on an as-converted basis using the $2.51 conversion price and the Company’s common stock price on the issuance date, and recorded in temporary equity. In addition, the Company recognized an anti-dilution liability at its issuance date fair value of $16,379,662 (see below and Note 11. Fair Value Measurements). The total consideration transferred, consisting of the fair value of the Series J Preferred Stock and the anti-dilution liability, together with $128,521 of directly attributable transaction costs, was recognized as an intangible asset of $17,238,716 representing the acquired right to use the licensed project technology (see Note 6. Intangible Assets).

 

The following table summarizes the initial accounting for the transaction:

 

Series J Preferred Stock, at issuance date fair value (temporary equity)  $730,533 
Anti-dilution liability, at issuance date fair value (Note 8 and 11)   16,379,662 
Transaction costs directly attributable to the asset acquisition   128,521 
Intangible asset recognized (acquired license right) (Note 6)  $17,238,716 

 

The Series J Preferred Stock is convertible into shares of Common Stock at the holder’s option at any time at an initial conversion price of $2.51 per share (the “Series J Conversion Price”), subject to customary adjustments for stock dividends, stock splits, and reclassifications. The number of Series J Conversion Shares initially may not exceed 291,049 (the “Maximum Issuance”); however, the Maximum Issuance is increased upon the occurrence of a Dilutive Issuance (as defined in the Series J Certificate of Designations) or a Dilutive Conversion. Once adjustments to the Maximum Issuance have been made in respect of (i) Dilutive Issuances and (ii) any exercises for cash of Common Stock Equivalents outstanding as of April 27, 2026, or approved for grant by the Board on such date, in an aggregate amount equal to $50 million, no further adjustments to the Maximum Issuance are made for any subsequent Dilutive Conversions or Dilutive Issuances. However, the Company’s obligation to issue shares of Common Stock to Kopin in respect of non-cash issuances, including conversions of preferred stock, is not subject to the $50 million cap and continues regardless of whether such cap has been reached. Anti-dilution shares issued to Kopin are delivered in the form of Series J Preferred Stock, computed on a preferred share equivalent basis at the Series J Conversion Price of $2.51 per share.

 

F-13

 

 

Upon liquidation, dissolution or winding up, the Series J Preferred Stock ranks senior to the Company’s Common Stock and its other junior capital stock with respect to preferences as to dividends, distributions and payments.

 

Holders are entitled to dividends of 6% per annum, accruing daily and payable semi-annually on each June 30 and December 31, in cash; provided that the Company may, at its sole option, elect to pay dividends in kind by issuing additional shares of Series J Preferred Stock having an aggregate stated value equal to the dividend then due. Unpaid dividends continue to accrue daily and compound on a semi-annual basis at the applicable rate until paid in full.

 

The Company identified anti-dilution provisions in the Series J Preferred Stock that are a freestanding financial instrument and required the recognition of an anti-dilution liability. The anti-dilution liability was initially recognized at its issuance date fair value of $16,379,662 and is measured at fair value on a recurring basis, with subsequent changes in fair value recognized in other income (expense), net in the unaudited condensed consolidated statements of operations. During the nine months ended September 30, 2026, the Company issued 3,530 additional shares of Series J Preferred Stock to Kopin under the anti-dilution provisions, a portion of which was applied against the $50 million cash issuance cap; the settlement of this obligation in Series J Preferred Stock reduced the anti-dilution liability by $5,339,631, with a corresponding increase in the temporary equity (see below). For the three and nine months ended September 30, 2026, the Company recognized a gain of $7,412,199 and a loss of $632,135, respectively, for the change in fair value of the anti-dilution liability. After these changes, the fair value of the anti-dilution liability was $11,672,166 as of September 30, 2026 (see Note 11. Fair Value Measurements).

 

Except as expressly set forth in the Series J Certificate of Designations or as otherwise required by law, the Series J Preferred Stock does not have any voting rights prior to conversion into shares of Common Stock; upon any such conversion, the holders of the converted shares are entitled to full voting rights as holders of Common Stock.

 

During the three and nine months ended September 30, 2026, the Company recognized $60,976 and $90,542 of accrued preferred dividends.

 

As of September 30, 2026, the carrying amount of the Series J Preferred Stock was $6,165,160.

 

Series K Preferred Stock

 

On April 27, 2026, the Company entered into a Securities Purchase Agreement with certain accredited investors (the “Series K Private Placement”), pursuant to which it issued 21,500 shares of newly designated Series K Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share, for aggregate gross proceeds of $21,500,000. The Series K Preferred Stock is classified as temporary equity (mezzanine equity) because it is redeemable for cash or other assets upon the occurrence of events not solely within the Company’s control, including certain triggering events, a change of control and certain bankruptcy related events.

 

The $21,500,000 of gross proceeds was allocated between the Series K Preferred Stock and the Series K Warrants based on their relative fair values at issuance, as described below. The initial carrying amount of the Series K Preferred Stock of $10,851,482 represents $12,714,483 of gross proceeds allocated to the Series K Preferred Stock, net of $1,863,001 of allocated issuance costs. The carrying amount is not accreted to the redemption amount because the Series K Preferred Stock is not currently redeemable and it is not probable that it will become redeemable, as the occurrence of the events that would permit or require redemption is not currently probable. Dividends on the Series K Preferred Stock accrue and increase the carrying amount, with a corresponding reduction of income available to common stockholders.

 

The Series K Preferred Stock and the Series K Warrants were issued together in a single transaction. Because the Series K Warrants are classified in stockholders’ equity, the Company allocated the $21,500,000 of gross proceeds between the two instruments based on their relative fair values at issuance. The issuance date fair values were $24,789,000 for the Series K Preferred Stock and $17,128,827 for the Series K Warrants. Issuance costs of $3,150,306, consisting of a $1,720,000 placement agent cash fee, $60,000 of other cash offering costs, and $1,370,306 representing the fair value of warrants issued to the placement agent, were allocated between the two instruments in proportion to the gross proceeds allocated to each. The following table summarizes the allocation of the Series K Private Placement proceeds and issuance costs:

 

   Issuance date
fair value
   Relative
fair value
   Gross
proceeds
allocated
   Issuance
costs
allocated
   Initial
carrying
amount
 
Series K Preferred Stock  $24,789,000    59%  $12,714,483   $(1,863,001)  $10,851,482 
Series K Warrants   17,128,827    41%   8,785,517    (1,287,305)   7,498,212 
Total  $41,917,827    100%  $21,500,000   $(3,150,306)  $18,349,694 

 

As of the issuance date, no bifurcated derivative liability was recognized because the fair value of the bifurcated features was determined to be $0; accordingly, no portion of the proceeds allocated to the Series K Preferred Stock was further allocated to a derivative.

 

Holders are entitled to dividends of 7% per annum, compounded quarterly and payable in arrears in cash out of funds legally available therefor, unless the Company and holder mutually agree to convert dividends into Common Stock at a price not less than the floor price. Dividends accrue at 15% per annum during the occurrence and continuance of a triggering event. The Series K Preferred Stock is convertible, at the holder’s option, into a fixed number of shares of Common Stock at $2.51 per share, and is currently convertible into up to 7,856,720 shares of Common Stock, settled in shares, subject to beneficial ownership limitations. The conversion price may be reduced upon the issuance of Common Stock or Common Stock Equivalents at a price below the then-effective conversion price (excluding standard anti-dilution adjustments). Upon a triggering event, a holder may require cash redemption at the greater of 130% of the conversion amount or 130% of a value based on the closing sale price of the Common Stock, and the shares are mandatorily redeemable at such price upon certain bankruptcy events. Upon a change of control, a holder may require redemption at a premium. Upon liquidation, holders are entitled, before any distribution to junior stock, to the greater of 125% of the conversion amount or the amount they would receive upon conversion. Holders vote with holders of Common Stock as a single class on an as-converted basis. The Series K Preferred Stock is a participating security because holders participate, on an as-converted basis, in dividends and other distributions of the Company’s assets declared to holders of Common Stock. Because the Company reported a net loss for the three and nine months ended September 30, 2026, there were no undistributed earnings to allocate to the Series K Preferred Stock under the two-class method, and the as-converted shares underlying the Series K Preferred Stock were excluded from the computation of diluted earnings per share for both periods because their effect would have been anti-dilutive.

 

For the three and nine months ended September 30, 2026, the Company recognized $356,843 and $616,037, respectively, of dividends on the Series K Preferred Stock, which are deducted in computing income available to common stockholders. The Company made dividend cash payments during the three months and nine months ended September 30, 2026, of $142,858.

 

F-14

 

 

During the three months ended September 30, 2026, Series K Preferred Stockholders converted 2,253 shares of Series K Preferred Stock for an aggregate amount of 897,535 shares of common stock. As a result, there were 19,247 shares of Series K Preferred Stock outstanding at September 30, 2026.

 

The Series K Preferred Stock includes a down-round provision that, when triggered, results in a deemed dividend reducing income available to common stockholders in computing basic earnings per share. The down-round feature was not triggered during the three and nine months ended September 30, 2026.

 

The Company determined that the Series K Preferred Stock is more akin to an equity-like host. The Company separated two embedded features: (i) an optional conversion upon a triggering event with a variable conversion price and (ii) a contingent dividend rate and the Company evaluated them for bifurcation from the equity host. No value was assigned to the variable conversion price feature because no variable price securities had been issued as of September 30, 2026, and the issuance of such securities is considered highly improbable. The contingent dividend rate feature was determined to be de minimis, as the triggering events could not be reasonably quantified using the Company’s credit risk and are considered highly improbable to occur. Accordingly, no bifurcated derivative liability was recognized as of the issuance date.

 

As of September 30, 2026, the carrying amount of the Series K Preferred Stock was $10,187,621, consisting of the $10,851,482 initial carrying amount plus $473,179 of net deemed and accrued dividends less $1,137,040 value of converted shares.

 

Common Stock Warrants

 

Series H-7 Warrants

 

In August 2023, the Company issued certain warrants to purchase common stock (the “Series H-7 Warrants”) pursuant to the Series H-7 Purchase Agreement (as defined above). The Series H-7 Warrants are entitled to certain anti-dilution adjustments, if the Company issues shares of its common stock at a lower price per share than the applicable exercise price. The exercise price of the Series H-7 Warrants is subject to adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of common stock, or securities convertible, exercisable or exchangeable for common stock, at a price below the then-applicable exercise price. As a result of the 2023 Reverse Stock Split, the exercise price of the Series H-7 Warrants was adjusted from $128.00 to $32.00 and the number of shares of common stock issuable upon exercise of the Warrants was adjusted proportionally to an additional 525,937 shares of common stock.

 

Pursuant to the share combination event adjustment provisions in the Series H-7 Warrants, the 2025 Reverse Stock Split adjusted the exercise price from $32.00 per share to $6.1933 per share and the number of shares of common stock issuable upon the exercise of the Series H-7 Warrants was adjusted proportionally to an additional 2,922,020 shares of common stock, for an aggregate of 3,623,270 Series H-7 Warrants outstanding.

 

The additional Series H-7 Warrants were determined to be subject to liability classification as they are considered to be indexed to the Company’s own stock but contain a provision where the holder of the Series H-7 Warrants have the right to require the Company to redeem the Series H-7 Warrants from the holder in cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of the Series H-7 Warrants at that time, in accordance with ASC 815. As such, the Company recorded the Series H-7 Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. See Note 11. Fair Value Measurements for inputs related to the Company’s use of the Black-Scholes Model to calculate the value of the Series H-7 Warrants.

 

As a result of the issuance of the Series K Preferred Stock, as described above, the conversion price of the Series H-7 Warrants was reduced from $6.1933 to $2.51 per share.

 

F-15

 

 

Series I Warrants

 

On August 6, 2025, the Company issued certain warrants to purchase up to an aggregate of 875,000 shares of the Company’s common stock (the “Series I Warrants”) pursuant to the Series I Purchase Agreement, with an exercise price of $8.00 per share and a date of expiration five years from the date of issuance. The Series I Warrants are entitled to certain anti-dilution adjustments, if the Company issues shares of its common stock at a lower price per share than the applicable exercise price.

 

The Series I Warrants were determined to be subject to liability classification as they are considered to be indexed to the Company’s own stock but contain a provision where the holder of the Series I Warrants have the right to require the Company to redeem the Series I Warrants from the holder in cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of the Series I Warrants at that time, in accordance with ASC 815. As such, the Company recorded the Series I Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black Scholes Model to calculate the fair value of these Series I Warrants. The fair value of the Series I Warrants of $3,981,034 was estimated at the date of issuance using the stock price of $5.92, an exercise price of $8.00, and the following weighted average assumptions: (i) dividend yield 0%; (ii) expected term of 5 years; (iii) equity volatility of 110%; and (iv) a risk-free interest rate of 4.21%.

 

In addition, the Company also issued the Series I Placement Agent Warrants (as defined herein) to purchase up to an aggregate of 140,000 shares of the Company’s common stock to the Placement Agents (as defined herein). The Company utilized the Black Scholes Model to calculate the value of the Series I Placement Agent Warrants issued during the year ended December 31, 2025. The fair value of the Series I Placement Agent Warrants of $636,966 was estimated at the date of issuance using the stock price of $5.92, an exercise price of $8.00, and the following weighted average assumptions: (i) dividend yield 0%; (ii) expected term of 5 years; (iii) equity volatility of 110%; and (iv) a risk-free interest rate of 4.21%.

 

In connection with the issuance of the Series K Preferred Stock and the Series K Warrants in April 2026, at an effective price of $2.51 per share, a price below the then-current exercise price of the Series I Warrants, the exercise price of the Series I Warrants was reduced from $8.00 to $2.51 per share. This reduction was effected by the anti-dilution provisions of the Series I Warrants and was not a discretionary modification by the Company. As described below under “Series H-7 and Series I Warrant Amendment”, the Series I Warrants were reclassified from liability to equity classification on August 26, 2025, and are not remeasured at fair value on a recurring basis. Because the reduction was effected through the Series I Warrants’ standard anti-dilution provision, no incremental fair value was recognized and no amount was recorded in the unaudited condensed consolidated financial statements as a result of the reduction.

 

Series H-7 and Series I Warrant Amendment

 

On August 26, 2025, the Company entered into an omnibus amendment (the “Warrant Amendment”) with the Required Holders (as defined in the Series H-7 Purchase Agreement and the Series I Purchase Agreement) to amend certain terms of the Series I Warrants and Series H-7 Warrants. The Warrant Amendment makes certain adjustments to the definition of a “Fundamental Transaction” and related provisions in each of the Warrants. In addition, the Warrant Amendment amends (i) the definition of the “Black Scholes Value” in the Series H-7 Warrants related to the volatility input, which is now calculated utilizing an expected volatility equal to the 30 day volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the trading day immediately following the earliest to occur of (1) the public disclosure of the applicable Fundamental Transaction and (2) the date of a holder’s request, and (ii) the definition of the “Black Scholes Consideration Value” in the Series H-7 Warrants related to the volatility input, which is now calculated utilizing an expected volatility equal to the 30 day volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the trading day immediately following the date of issuance of the applicable options, convertible securities or Adjustment Right (as defined in the Series H-7 Warrants). Further, the Warrant Amendment removes the provision in the Series H-7 Warrants providing for an adjustment in the exercise price of the Series H-7 Warrants upon (a) the increase or decrease of the purchase or exercise price of any options, (b) the issuance of additional consideration upon the conversion of any convertible securities or (c) the increase or decrease of the rate of conversion of any convertible securities.

 

The Warrant Amendment resulted in the Series I Warrants and Series H-7 Warrants to be considered equity classified in accordance with ASC 815. The fair value of the Series I Warrants and Series H-7 Warrants on August 26, 2025, of $18,608,000, was reclassified from warrant liability to additional paid-in capital. The Company remeasured the Series I Warrants and Series H-7 Warrants at fair value as of August 26, 2025, and recognized the change in fair value as a non-cash loss of $17,971,034. The fair value of the Series I Warrants and Series H-7 Warrants of $18,608,000 was estimated at August 26, 2025, utilizing the Black Scholes Model using the following weighted average assumptions: dividend yield 0%; remaining term of 4.95 years and 2.96 years, respectively; equity volatility of 105% and 97%, respectively; and a risk-free interest rate of 3.7% and 3.6%, respectively.

 

F-16

 

 

Series K Warrants

 

In connection with the Series K Private Placement, the Company issued warrants (the “Series K Warrants”) to purchase an aggregate of up to 8,565,737 shares of Common Stock at an exercise price of $2.51 per share. The Series K Warrants were issued together with the Series K Preferred Stock as part of the same financing to provide investors additional upside participation in the Company’s Common Stock. The Series K Warrants are exercisable immediately and expire on the fifth anniversary of the date of issuance. Each Series K Warrant entitles the holder to purchase one share of Common Stock for each share of Common Stock into which the corresponding Series K Preferred Stock is convertible. The Series K Warrants are not listed on any national securities exchange.

 

The Series K Warrants are exercisable in whole or in part at any time, for cash or by cashless exercise. The exercise price is subject to customary anti-dilution adjustments and may be reduced to the base share price upon the Company’s issuance of Common Stock or Common Stock Equivalents at an effective price below the then effective exercise price.

 

The Series K Warrants are classified in stockholders’ equity. Of the $21,500,000 of gross proceeds, $8,785,517 was allocated to the Series K Warrants based on their relative fair value and recorded in additional paid-in capital, and $1,287,305 of allocated issuance costs was recorded as a reduction of additional paid-in capital. The fair value of the Series K Warrants at issuance was $17,128,827, determined using a Black-Scholes option pricing model. See “Series K Preferred Stock” above. Because the Series K Warrants are classified in equity, they are not remeasured at fair value.

 

In connection with the Series K Private Placement, the Company issued warrants to purchase 685,259 shares of Common Stock to the placement agent (the “Placement Agent Warrants”), on the same terms as the Series K Warrants, as compensation for placement agent services. The Placement Agent Warrants are accounted for under ASC 718 as nonemployee share-based compensation and are equity-classified. The fair value of the Placement Agent Warrants of approximately $1,370,306 was determined using a Black-Scholes option pricing model and included in the $3,150,306 of total issuance costs of the Series K Private Placement.

 

The Series K Warrants are participating securities and are reflected in diluted earnings per share under the treasury stock method to the extent they are dilutive. The Series K Warrants were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2026, because the exercise price exceeded the average market price of the Common Stock during the period and they were antidilutive. The Series K Warrants include a down-round feature under which the exercise price may be reduced upon a dilutive issuance; the value of the effect of any down-round feature triggered during the reporting period is recognized as a deemed dividend reducing income available to common stockholders in computing basic earnings per share. The Series K Warrant down-round feature was not triggered during the three and nine months ended September 30, 2026.

 

As of September 30, 2026, the Company had 8,565,737 Series K Warrants outstanding.

 

Waiver Warrants

 

Pursuant to the April 2026 Amendments, the Company issued warrants to purchase up to an aggregate of 1,000,000 shares of Common Stock (the “Waiver Warrants”) to the Required Holders, pro rata based on the number of shares of Series H-7 Preferred Stock and Series I Preferred Stock held as of the date of the April 2026 Amendments, as consideration for the Required Holders’ consent to the amendments to the Series H-7 and Series I Certificate of Designations. The Waiver Warrants are exercisable immediately at an exercise price of $5.00 per share and expire five years from the date of issuance.

 

The Waiver Warrants are classified within stockholders’ equity in accordance with ASC 815-40 and are not remeasured at fair value on a recurring basis. In connection with their issuance, the Company recognized a charge of $1,565,000 in other income (expense), net in the unaudited condensed consolidated statement of operations, representing the fair value of the consideration provided to the Required Holders for their consent to the April 2026 Amendments.

 

Altucher Consulting Warrants

 

On August 4, 2025, the Company entered into a consulting agreement (the “Prior Altucher Consulting Agreement”) with James Altucher and Z-List Media, Inc. (together, the “Prior Consultant”), pursuant to which, the Company issued warrants to purchase up to an aggregate of 1,000,000 shares of common stock (the “Prior Consultant Warrants”), consisting of four tranches at exercise prices ranging from $8.00 to $17.50 per share. The grant date fair value of the Prior Consultant Warrants was $4,891,747, of which $1,834,405 had been recognized as compensation cost through the modification date discussed below.

 

F-17

 

 

On April 27, 2026, the Company and the Prior Consultant agreed to amend and restate the Prior Altucher Consulting Agreement by entering into an amended and restated consulting services agreement (the “Altucher Consulting Agreement”) with JD Advisors, LLC, an affiliate of the Prior Consultant (the “Consultant”). In connection with the Altucher Consulting Agreement, the Consultant entered into a warrant cancellation agreement pursuant to which the Prior Consultant Warrants (warrants to purchase up to 1,000,000 shares of common stock) were cancelled, and the Company issued to the Consultant new warrants to purchase up to an aggregate of 900,000 shares of common stock (the “Consultant Warrants”), consisting of: (i) a warrant to purchase up to 300,000 shares at an exercise price of $3.00 per share, immediately exercisable (the “First Tranche”), (ii) a warrant to purchase up to 200,000 shares at an exercise price of $6.00 per share, exercisable six months from issuance, (iii) a warrant to purchase up to 200,000 shares at an exercise price of $9.00 per share, exercisable twelve months from issuance, and (iv) a warrant to purchase up to 200,000 shares at an exercise price of $12.00 per share, exercisable eighteen months from issuance, in each case with a term of five years from the date of issuance. The Altucher Consulting Agreement has a term of two years from April 27, 2026.

 

The Company accounted for the cancellation and reissuance as a modification of an equity classified share-based payment award under ASC 718-20. Management determined that the service-based vesting conditions of the Prior Consultant Warrants were probable of achievement immediately before the modification and that the vesting conditions of the Consultant Warrants are probable of achievement after the modification, resulting in a Type I (probable-to-probable) modification.

 

The Company determined the fair value of the Prior Consultant Warrants immediately before cancellation and the fair value of the Consultant Warrants immediately after issuance using the Black-Scholes option pricing model. The fair value of the Prior Consultant Warrants immediately before modification was $1,067,000, using the following assumptions: stock price of $2.51, exercise prices ranging from $8.00 to $17.50, remaining term of 4.27 years, expected volatility of 96.0%, dividend yield of 0%, and a risk-free rate of 3.9%. The fair value of the Consultant Warrants immediately after modification was $1,327,000, using the following assumptions: stock price of $2.51, exercise prices ranging from $3.00 to $12.00, term of 5.00 years, expected volatility of 93.0%, dividend yield of 0%, and a risk-free rate of 3.9%. The modification resulted in incremental fair value of $260,000.

 

The Company recognized total compensation cost of $3,317,342 in connection with the modification, comprised of the $3,057,342 of unrecognized grant date fair value of the Prior Consultant Warrants plus $260,000 of incremental fair value described above. This amount is recognized ratably over the two-year service period ending April 27, 2028. As each tranche of the Consultant Warrants becomes exercisable, the Company records a prepaid expense equal to that tranche’s pro-rata share of the total compensation cost, which is then amortized to compensation expense over the service period. As of September 30, 2026, the Company recorded $1,105,781 to prepaid expense upon the reissuance of the First Tranche, of which $414,668 remained as the prepaid balance after amortization through September 30, 2026.

 

For the three and nine months ended September 30, 2026, the Company recorded $414,668 and $1,506,404 of stock-based compensation related to the Prior Consultant Warrants and the First Tranche of the Consultant Warrants under general and administrative expenses on the unaudited condensed consolidated statement of operations.

 

NOTE 9. STOCK-BASED COMPENSATION

 

Stock Option Awards

 

On July 7, 2026, the Company granted options to purchase an aggregate of 48,000 shares of common stock to a certain employee, with an exercise price of $2.85 per share and a 10-year contractual term. The options vest 25% on October 7, 2026, 25% on January 7, 2027, 25% on April 7, 2027, and 25% on July 7, 2027, subject to continued service. The grant date fair value of the options was $89,280 using the Black-Scholes option pricing model.

 

On August 14, 2026, the Company granted options to purchase an aggregate of 1,716,564 shares of common stock to Mr. Murray, a consultant, in connection with the Murray Consulting Agreement (see Note 16. Commitments and Contingencies), with an exercise price of $2.75 per share and a 5-year contractual term. The options vest in three installments on August 14, 2027, August 14, 2028, and August 14, 2029, subject to continued service. Vested options are initially exercisable for up to 242,319 shares, and the exercisable amount increases as the Company issues additional shares of common stock, up to the full 1,716,564 shares. The Company has assessed it as probable that all of the options will become exercisable. The grant date fair value of the options was $3,141,312 using the Black-Scholes option pricing model.

 

The Company recognized $689,985 and $965,157 in stock-based compensation expense for the three and nine months ended September 30, 2026.

 

F-18

 

 

Restricted Stock Awards

 

On June 18, 2026, the Company granted 358,566 restricted shares of common stock to Joshua Silverman, the Company’s Chief Executive Officer, with a grant date fair value of $2.51 per share and an aggregate fair value of $900,000. The award vests 25% on the grant date and 25% on each of the next three fiscal quarter-ends, subject to continued service.

 

During the three and nine months ended September 30, 2026, 89,642 and 268,925 shares vested, respectively. The Company withheld 44,820 and 134,460 of the vested shares, respectively, to satisfy the holder’s minimum statutory tax withholding obligations, with an aggregate value of $102,190 and $380,074, respectively, based on the closing price of the Company’s common stock on each vesting date. The withheld shares were not issued and are accounted for as a repurchase of common stock, recorded as a reduction of additional paid-in capital. As of September 30, 2026, $380,074 of the related tax withholding obligation was unpaid and included in accrued expense.

 

The Company recognized $276,506 and $675,000 of stock-based compensation expense related to the award for the three and nine months ended September 30, 2026, respectively. As of September 30, 2026, unrecognized compensation cost related to the award of $225,000 is expected to be recognized through December 31, 2026, and 89,642 shares remained unvested.

 

NOTE 10. DERIVATIVE INSTRUMENTS

 

The Company recorded a derivative liability related to the derivatives embedded within the Series I Preferred Stock, primarily related to make-whole and penalty dividend features (see Note 8. Stockholders’ Equity). Changes in fair value are recognized in earnings in change in fair value – derivative liability in the unaudited condensed consolidated statements of operations. This note presents only the embedded derivative bifurcated from the Series I Preferred Stock. The embedded features of the Series K Preferred Stock were evaluated and determined not to require bifurcation, as discussed in Note 8. Stockholders’ Equity. The anti-dilution liability associated with the Series J Preferred Stock is accounted for separately and is disclosed in Note 11. Fair Value Measurements.

 

The following table presents the fair value of the Company’s embedded derivatives as of September 30, 2026:

 

   Balance Sheet Location  Fair Value 
Series I derivative liability  Non-current liabilities  $89,000 
Total     $89,000 

 

For the three and nine months ended September 30, 2026, the Company recognized a gain of $- and $37,000, respectively, related to embedded derivatives.

 

NOTE 11. FAIR VALUE MEASUREMENTS

 

The Company measures certain assets and liabilities at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurements.

 

The following table presents the fair value hierarchy of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2026:

 

   Level 1   Level 2   Level 3   Total 
Prime institutional money market fund  $962,798   $   -   $-   $962,798 
U.S. Treasury Bills – over 90 days   12,884,850    -    -    12,884,850 
Anti-dilution liability   -    -    (11,672,166)   (11,672,166)
Derivative liabilities   -    -    (89,000)   (89,000)
Total  $13,847,648   $-   $(11,761,166)  $2,086,482 

 

Level 1 inputs consist of quoted prices in active markets for identical assets. The Company’s derivative liability and anti-dilution liability are classified within Level 3 of the fair value hierarchy because the valuations incorporate significant unobservable inputs.

 

F-19

 

 

The following table sets forth a summary of the change in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

 

   Series I   Series H-7   Series J Anti-dilution   Total 
Balance – December 31, 2025  $19,000   $-   $-   $19,000 
Change in fair value, three months ended March 31, 2026   6,000    -    -    6,000 
Change in fair value, April 1, 2026 through Omnibus Amendment Date   14,000    -    -    14,000 
Settlement of derivative liability upon Omnibus Amendment   (39,000)   -    -    (39,000)
Issuance of derivative liability upon Omnibus Amendment   124,000    22,000    -    146,000 
Issuance of Series J Preferred Stock   -    -    16,379,662    16,379,662 
Issuance of shares in settlement of anti-dilution provisions   -    -    (4,871,467)   (4,871,467)
Change in fair value   -    -    8,044,334    8,044,334 
Change in fair value, Omnibus Amendment date through June 30, 2026   (35,000)   (22,000)   -    (57,000)
Issuance of shares in settlement of anti-dilution provisions   -    -    (468,164)   (468,164)
Change in fair value, three months ended September 30, 2026   -    -    (7,412,199)   (7,412,199)
Total  $89,000   $-   $11,672,166   $11,761,166 

 

During the three months ended September 30, 2026 and 2025, the Company recorded a gain of $- and $179,000, respectively, related to the change in fair value of the derivative liability which is recorded in other income (expense), net on the unaudited condensed consolidated statements of operations.

 

During the nine months ended September 30, 2026 and 2025, the Company recorded a gain of $37,000 and $2,840,000, respectively, related to the change in fair value of the derivative liability which is recorded in other income (expense), net on the unaudited condensed consolidated statements of operations.

 

The Company estimated the $89,000 and $19,000 fair value of the bifurcated embedded derivative at September 30, 2026 and December 31, 2025, respectively, using a Monte Carlo simulation model, with the following inputs:

 

   September 30,   December 31, 
   2026   2025 
Volatility   100.0%   130.0%
Time to maturity   1.07    1.18 
Discounted market interest   29.33%   7.5%
Dividend rate   7.0%   7.0%
Penalty dividend rate   15.0%   15.0%
Probability of default   6.0%   9.0%

 

The Company measures the anti-dilution liability associated with the Series J Preferred Stock at fair value on a recurring basis (see Note 8. Stockholders’ Equity). The liability is classified within Level 3 of the fair value hierarchy because the valuation incorporates significant unobservable inputs, including the number of potential shares issuable under the anti-dilution provisions, the $50 million cap on cash issuances, and the outstanding options, warrants and preferred stock.

 

During the three and nine months ended September 30, 2026, the Company recorded a gain of $7,412,199 and a loss of $632,135, respectively, related to the change in fair value of the anti-dilution liability, which is recorded in other income (expense), net on the unaudited condensed consolidated statements of operations.

 

The valuation of the Company’s Level 3 financial instruments is inherently subjective, as it requires the use of significant unobservable inputs. Changes in these inputs could result in materially different fair value measurements. In particular, increases in the Company’s stock price, expected volatility, or expected term, as well as decreases in the discount rate or probability of default, would generally result in a higher fair value of the derivative and warrant liabilities, while decreases in these inputs would generally result in a lower fair value. The Company evaluates the sensitivity of its fair value measurements to changes in significant unobservable inputs as part of its valuation process.

 

NOTE 12. SEGMENT REPORTING

 

The Company currently operates as one operating segment, which is also the sole reportable segment. The Company’s CODM is its Chief Executive Officer and Principal Executive Officer, who assesses performance and makes all resource allocation decisions based on consolidated net income (loss).

 

The CODM does not review discrete financial information or separate performance metrics for any individual business activity and all decisions are made based on consolidated results. The measure of segment assets is consolidated total assets as presented on the consolidated balance sheets.

 

F-20

 

 

During the nine months ended September 30, 2026, the Company initiated a strategic transformation to the design and development of fabless semiconductor technologies for AI data center infrastructure. The Company’s single operating segment now derives its activities principally from these semiconductor development activities, including the joint development arrangement with Kopin Corporation described in Note 16. Commitments and Contingencies. During 2025, the Company initiated a digital asset treasury strategy associated with the stablecoin ecosystem. The Company disposed of all of its digital asset holdings during the nine months ended September 30, 2026, and does not intend to develop this strategy further (see Note 7. Digital Assets). During the nine months ended September 30, 2026, the Company also sold the assets associated with its electric vehicle operations (see Note 15. Sale of Legacy Electric Vehicle Assets).

 

These changes affected the nature of the business activities conducted within the Company’s single operating segment but did not change the Company’s basis of segmentation or the composition of its reportable segment. The CODM continued to assess performance and allocate resources on a consolidated basis throughout all periods presented, and there were no changes from the last annual report in the basis of segmentation or in the measure of segment profit or loss. Accordingly, prior-period segment information has not been recast.

 

In addition to the significant expense categories included within net loss presented on the Company’s Condensed Consolidated Statements of Operations, see below for disaggregated amounts that comprise consulting and personnel expenses:

 

   2026   2025 
   Three Months Ended September 30, 
   2026   2025 
Consulting expenses  $9,352,874   $1,411,462 
Personnel expenses   99,999    313,930 
Other expenses*   3,056,980    1,091,128 
Total operating expenses  $12,509,853   $2,816,520 

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Consulting expenses  $10,167,630   $3,310,303 
Personnel expenses   400,159    1,013,612 
Other expenses*   6,972,195    2,015,431 
Total operating expenses  $17,539,984   $6,339,346 

 

* Other expenses primarily consists of rent, property taxes, insurance, depreciation, licenses and business taxes, software subscription fees, issuance cost, bad debt, dues and subscriptions, travel and entertainment, and marketing.

 

Other income (expense) segment items for the three and nine months ended September 30, 2026, were $7,602,350 and $(2,264,025), respectively, and consist primarily of changes in fair value on digital assets, changes in fair value of derivative and warrant liabilities, and interest expense.

 

F-21

 

 

NOTE 13. LEASES

 

During the fiscal year ended December 31, 2025, the Company entered into a sublease arrangement with a third party for the remaining term of the head lease, as the underlying facility was no longer being utilized due to the pause in the Company’s electric vehicle manufacturing operations. The sublease term does not extend beyond the noncancelable period of the head lease. There have been no material changes to the Company’s lease arrangements since December 31, 2025.

 

The following table summarizes sublease income for the three and nine months ended September 30, 2026 and 2025:

 

   2026   2025 
   Three Months Ended September 30, 
   2026   2025 
Sublease income  $92,941   $   - 

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Sublease income  $271,850   $   - 

 

NOTE 14. RELATED-PARTY TRANSACTIONS

 

Kopin Corporation

 

Kopin Corporation (“Kopin”) holds approximately 19.9% of the Company’s outstanding common stock on an as-converted, fully diluted basis through the Series J Convertible Preferred Stock and is the Company’s counterparty under the Joint Development and License agreement (the “JDA”) and the related Commercial Supply Agreement (see Note 8. Stockholders Equity, Note 11. Fair Value Measurements, and Note 16. Commitments and Contingencies). Michael Murray, Kopin’s Chief Executive Officer, serves a Chairman of the Joint Steering Committee established under the JDA. As a result of its ownership interest and its role as the Company’s counterparty under the JDA and the Supply Agreement, the Company has determined that Kopin is a related party.

 

The Company’s nonrefundable advance payments to Kopin for development services under the JDA are capitalized within prepaid expenses and other current assets and recognized as research and development expense as Kopin performs the related services. The Company recognized research and development expense related to the JDA as presented in the table below. As of September 30, 2026, the unamortized balance of the advance was $0.

 

Murray Consulting Agreement

 

Michael Murray, the Chief Executive Officer of Kopin, serves as Chairman of the Joint Steering Committee under the Murray Consulting Agreement and holds the Murray Option (see Note 9. Stock-Based Compensation and Note 16. Commitments and Contingencies). The Company recognized stock-based compensation expense related to the Murray Options during the three and nine months ended September 30, 2026. The Company pays Mr. Murray no cash compensation, and no amounts were due to or from Mr. Murray as of September 30, 2026.

 

Villareal Consulting Services

 

Gilbert Villarreal, the former president of the Company’s subsidiary, AYRO Operating, through GLV Ventures and Electric Power, entities owned and controlled by Mr. Villarreal, has been providing consulting services to the Company in connection with the reengineering of the Company’s Vanish at a rate of $30,000 per month. During the nine months ended September 30, 2026, Mr. Villarreal relinquished his role as president of AYRO Operating, and accordingly the Company ceased incurring related-party transactions with his controlled entities as of that time. The Company incurred no related-party transactions with Mr. Villarreal’s controlled entities during the three months ended September 30, 2026.

 

Related-party incurred expenses and liabilities are presented below:

 

Related-Party Incurred Expenses

 

Related Party  Classification  2026   2025 
      Three Months Ended September 30, 
Related Party  Classification  2026   2025 
Kopin Corporation   Research and development   $ 9,352,874     $ -  
Michael Murray(1)   General and administrative     246,947       -  
Electric Power Energy  Research and development   -    216,039 
Electric Power Energy  General and administrative   -    243,549 
Total     $9,599,821   $459,588 

 

Related Party  Classification  2026   2025 
      Nine Months Ended September 30, 
Related Party  Classification  2026   2025 
Kopin Corporation   Research and development   $ 10,022,766     $ -  
Michael Murray(1)   General and administrative     246,947       -  
Electric Power Energy  Research and development   -    390,204 
Electric Power Energy  General and administrative   200,000    475,294 
Total     $10,469,713   $865,498 

 

Related-Party Liabilities

 

Related Party  Classification  September 30,
2026
   December 31,
2025
 
Kopin Corporation   Accrued expenses and other current liabilities   $ 1,022,766     $ -  
Electric Power Energy  Accrued expenses and other current liabilities   -    5,000 
Total     $-   $5,000 

 

(1)The amount attributable to Mr. Murray represents non-cash stock-based compensation on the Muray Options (see Note 9. Stock-Based Compensation). The Company pays Mr. Murray no cash compensation.

 

NOTE 15. SALE OF LEGACY ELECTRIC VEHICLE ASSETS

 

The Company’s operating subsidiary, AYRO Operating Company, Inc., historically designed, manufactured, and sold compact, sustainable electric vehicles (the “Legacy EV Business”). Operations of the Legacy EV Business ceased during 2025, the related long-lived assets had previously been written down to a carrying value of zero. On June 11, 2026, AYRO Operating Company, Inc. entered into an Asset Purchase Agreement to sell substantially all of the tangible and intangible assets used in the Legacy EV Business, including vehicle and parts inventory, intellectual property, engineering designs and technical data, production and fabrication equipment, vehicles, and office furnishings, for aggregate consideration of $250,000, consisting of $25,000 paid at closing and $112,500 payable on each of the six-month and twelve-month anniversaries of closing, plus the assumption by the buyer of certain liabilities related to the Legacy EV Business. Cash, receivables, EV batteries and battery packs, and certain other assets were excluded from the sale.

 

F-22

 

 

The Company recognized a gain of $218,803 on the sale, reflecting the consideration received, less transaction costs, given the assets’ carrying value of zero at the date of sale. The gain is included in gain on sale of assets within other income (expense), net in the unaudited condensed consolidated statement of operations. Because the Company operates as a single reportable segment, the Legacy EV Business is not presented separately for segment reporting purposes (see Note 12. Segment Reporting).

 

NOTE 16. COMMITMENTS AND CONTINGENCIES

 

Joint Development and License Agreement

 

On April 27, 2026, the Company entered into the JDA with Kopin, to collaborate on the development and commercialization of Kopin’s interface for GPU-to-GPU connectivity. Under the JDA, the Company has committed to pay Kopin up to $15,000,000 for the development of the project technology through achievement of a successful prototype demonstration (a “Successful Demo”), payable in installments under a time-based funding schedule. The Company has also agreed to maintain at least $5,000,000 of funds in a segregated account to cover development plan needs.

 

During the nine months ended September 30, 2026, the Company made nonrefundable advance payments in the aggregate amount of $9,000,000 to Kopin for future research and development services under the JDA. The advance has been capitalized and is included in prepaid expenses and other current assets in the unaudited condensed consolidated balance sheets, and is recognized as research and development expense as Kopin performs the related development services. As of September 30, 2026, the unamortized balance of the advance was $0 and $1,022,766 was accrued and payable to Kopin. For the three and nine months ended September 30, 2026, the Company recognized $9,352,874 and $10,022,766 in research and development expense related to the JDA. As of September 30, 2026, the Company’s remaining funding commitment under the JDA was approximately $6,000,000.

 

In consideration for Kopin’s grant of the license to the project technology, the Company issued to Kopin shares of the Company’s Series J Convertible Preferred Stock. The Series J Convertible Preferred Stock is recorded in temporary equity (mezzanine equity), including a related anti-dilution liability, and is described further in Note 8. Stockholders’ Equity.

 

Following achievement of a Successful Demo, the parties have agreed to negotiate in good faith for one year toward a production plan for deployment of the project technology, which could require additional payments by the Company of approximately $15,000,000 to $25,000,000. This obligation is contingent on achievement of a Successful Demo and is not currently committed.

 

Supply Agreement

 

Concurrently with the JDA, the Company entered into a Commercial Supply Agreement (the “Supply Agreement”) with Kopin under which Kopin appointed the Company as the exclusive seller of any products incorporating the project technology to end users worldwide (subject to certain exceptions). The Company is required to purchase its entire requirements for such products from Kopin, subject to certain exceptions, for an initial term of four years with automatic one-year renewal periods unless either party provides notice of non-renewal.

 

Other than $1,022,766 accrued for development services performed by Kopin as of September 30, 2026, the Company does not believe it is probable that a liability has been incurred in connection with the JDA or Supply Agreement as of September 30, 2026. Should the Company fail to fulfill its funding or other obligations under the JDA or Supply Agreement, it could be required to assign its rights in the project technology to Kopin or have other obligations accelerate, which could be material.

 

Murray Consulting Agreement

 

On August 14, 2026, the Company entered into a consulting agreement with Michael Murray (the “Murray Consulting Agreement”) under which Mr. Murray serves as Chairman of the Joint Steering Committee (the “JSC”) established under the JDA. The JSC oversees the joint development program with Kopin, and Mr. Murray provides strategic guidance on the Company’s technology roadmap and joint research and development priorities. Mr. Murray is the Chief Executive Officer of Kopin, a holder of 19.9% of the Company’s equity through Series J Convertible Preferred Stock and the Company’s counterparty under the JDA and Supply Agreement (see Note 14. Related-Party Transactions).

 

The Murray Consulting Agreement remains in effect for as long as the JDA remains in effect. Mr. Murray may terminate the agreement on 60 days’ written notice; the Company has no right to terminate.

 

The Company pays Mr. Murray no cash compensation or expense reimbursement under the Murray Consulting Agreement. His sole compensation is options to purchase up to 1,716,564 shares of common stock (the “Murray Options”), which the Company granted on August 14, 2026 (see Note 9. Stock-Based Compensation).

 

NOTE 17. INCOME TAXES

 

No income tax benefit was recognized on losses incurred during the three and nine months ended September 30, 2026 and 2025 due to the Company’s full valuation allowance position against deferred tax assets.

 

F-23

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that,” “may,” “plans,” “seeks,” “projects,” “targets,” “would” and “will” or the negative of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, but are not limited to, future financial and operating results, the company’s plans, objectives, expectations and intentions, statements concerning the Company’s expectations regarding the development and commercialization of its fabless semiconductor technologies for AI data center infrastructure, the Company’s collaboration with the Kopin Corporation, and other statements that are not historical facts. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from our historical experience and our present expectations, or projections described under the sections in this Form 10-Q and our other reports filed with the SEC titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

For a more detailed discussion of other factors that may affect our business and that could cause our actual results to differ materially from those projected in these forward-looking statements, see the risk factors and uncertainties set forth in Part II, Item 1A of this Form 10-Q and in Part I, Item 1A of our Annual Report on Form 10-K as filed with the SEC on March 30, 2026. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise, except as required by law.

 

F-24

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following management’s discussion and analysis should be read in conjunction with our historical consolidated financial statements and the related notes thereto. This management’s discussion and analysis contains forward-looking statements, such as statements of our plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”) that could cause actual results or events to differ from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. See “Cautionary Note Regarding Forward-Looking Statements.”

 

References in this management’s discussion and analysis to “we,” “us,” “our,” “the Company,” “our Company,” or “Fabric.AI” refer to Fabric.AI and its subsidiary.

 

Overview

 

The Company is a fabless semiconductor company focused on the design and development of optical interconnect technologies and other system-critical semiconductor solutions for artificial intelligence (“AI”) data center infrastructure. In April 2026, we commenced a strategic transition toward a new business model focused on the design and development of fabless semiconductor technologies for AI data center infrastructure, including MicroLED-based optical interconnects and other system-critical semiconductor solutions intended to enable faster, more efficient, and more scalable AI workloads. In connection with this strategic transformation, effective April 28, 2026, the Company changed its corporate name from StableX Technologies, Inc. to Fabric.AI, Inc. and changed its ticker symbol on The Nasdaq Stock Market LLC (“Nasdaq”) from “SBLX” to “FABC,” which commenced trading under the new symbol on April 29, 2026. The Company’s common stock, par value $0.0001 per share (the “Common Stock”), is listed on Nasdaq.

 

Our initial product under development is the Neural I/o™ chip (the “Neural I/o chip”), a micro light-emitting diode (“MicroLED”) based optical interconnect being developed in collaboration with Kopin Corporation, a Delaware corporation (“Kopin”) (Nasdaq: KOPN), pursuant to a Joint Development and License Agreement dated April 27, 2026 (the “JDA”), by and between the Company and Kopin. The Neural I/o chip is intended to replace traditional electrical interconnects with optical links to enable high-bandwidth, low-latency communication between compute nodes, with an initial focus on GPU-to-GPU connectivity for AI data center applications.

 

We have a limited operating history in the AI semiconductor industry. We are a development-stage company with no revenue from our semiconductor operations to date, and there can be no assurance that we will successfully develop, commercialize, or achieve market acceptance of our technologies.

 

Our Strategy

 

Our strategy is to develop and commercialize semiconductor technologies that address what we believe are critical performance constraints in AI data center infrastructure. As AI workloads have grown in complexity and scale, we believe that the performance of interconnect subsystems, the components that enable data movement between processors, memory, and other compute nodes, has become an increasingly significant constraint on overall system performance. Our strategy is focused on the following key elements:

 

  ● Develop and commercialize MicroLED-based optical interconnect technology. Our near-term focus is the development of the Neural I/o chip, which we believe has the potential to offer advantages in power efficiency, bandwidth density, and cost relative to existing copper-based and laser-based interconnect solutions.

 

1

 

 

  ● Leverage our collaboration with Kopin Corporation. We are developing our initial MicroLED-based interconnect technology in collaboration with Kopin, which we believe is the only company currently capable of producing programmable MicroLEDs. Both companies jointly develop and share in the intellectual property created through this partnership.
     
  ● Expand into additional system-critical semiconductor technologies. Over time, we intend to develop a broader suite of semiconductor technologies designed for AI workloads, beginning with interconnects and potentially expanding into other system-critical components.
     
  ● Pursue strategic relationships with potential customers. We are engaged in preliminary discussions with leading AI and hyperscale technology companies regarding the potential integration of our technology into their systems, and we have entered into non-disclosure agreements with two chipmakers. There can be no assurance that any of these discussions will result in definitive agreements or revenue.

 

As of the date of this filing, we have not generated any revenue from our semiconductor operations. We are in the early stages of business development and have entered into non-disclosure agreements with two chipmakers in connection with preliminary discussions regarding MicroLED-based optical interconnect technology. We are also engaged in preliminary discussions with certain AI and hyperscale technology companies regarding the potential integration of our interconnect technology into their systems. These discussions are at a preliminary stage and may not progress to definitive agreements, and there can be no assurance that any of these discussions or non-disclosure agreements will result in commercial agreements, supply arrangements, or revenue.

 

Equity Incentive Grants

 

On July 7, 2026, the Company granted options to purchase an aggregate of 48,000 shares of common stock to a certain employee, with an exercise price of $2.85 per share and a 10-year contractual term. The options vest 25% on October 7, 2026, 25% on January 7, 2027, 25% on April 7, 2027, and 25% on July 7, 2027, subject to continued service and subject to the terms and conditions of the Plan.

 

Murray Consulting Agreement

 

On August 14, 2026, we entered into a consulting agreement with Michael Murray, Chief Executive Officer of Kopin, under which he serves as Chairman of the Joint Steering Committee overseeing our joint development program with Kopin. Because Kopin holds our Series J Preferred Stock and is our counterparty under the JDA and Supply Agreement, this is a related-party arrangement (see Note 14. Related-Party Transactions). The agreement remains in effect for as long as the JDA does. Mr. Murray may terminate the consulting agreement on 60 days’ notice, and we have no right to terminate. Mr. Murray receives no cash compensation. Mr. Murray’s sole compensation is options to purchase up to 1,716,564 shares of common stock, which we granted on August 14, 2026. We recognized stock-based compensation of $246,947 for these options in the three and nine months ended September 30, 2026, with $2,894,365 of unrecognized expense remaining (see Note 9. Stock-Based Compensation).

 

On August 14, 2026, the Company granted options to purchase an aggregate of 1,716,564 shares of common stock to Mr. Murray, a consultant, in connection with the Murray Consulting Agreement (see Note 16. Commitments and Contingencies), with an exercise price of $2.75 per share and a 5-year contractual term. The options vest in three installments on August 14, 2027, August 14, 2028, and August 14, 2029, subject to continued service. Vested options are initially exercisable for up to 242,319 shares, and the exercisable amount increases as the Company issues additional shares of common stock, up to the full 1,716,564 shares. The Company has assessed it as probable that all of the options will become exercisable. The grant date fair value of the options was $3,141,312 using the Black-Scholes option pricing model.

 

Series J Anti-Dilution Issuances

 

During the three months ended September 30, 2026, pursuant to the anti-dilution provisions of the Series J Certificate of Designations, we issued an aggregate of 450 additional shares Series J Preferred Stock to Kopin as a result of the conversion of 2,253 shares of Series K Preferred Stock into 897,535 shares of Common Stock during the quarter. The additional shares are convertible into approximately 179,417 shares of Common Stock at the Series J Conversion Price of $2.51 per share. We did not receive any additional consideration for the issuance, which reduced the anti-dilution liability by $468,164 (see Note 8. Stockholders’ Equity and Note 11. Fair Value Measurements).

 

2

 

 

Components of Results of Operations

 

Revenue

 

The Company has not generated revenue during the three and nine months ended September 30, 2026 or 2025. The Company does not expect to generate revenue until it has successfully developed and commercialized products, including the Neural I/oTM chip being developed under the JDA.

 

Cost of Goods Sold

 

Cost of goods sold primarily consists of costs of materials and personnel costs associated with manufacturing operations, and an accrual for post-sale warranty claims. The Company incurred cost of goods sold of $0 and $717,120 during the three months ended September 30, 2026 and 2025, respectively, and $0 and $956,160 during the nine months ended September 30, 2026 and 2025, respectively. The decrease was due to the absence of in 2026 of the Vanish inventory impairment charges recorded in 2025. The Company does not expect to incur significant cost of goods sold until it has commenced commercialization of products incorporating its semiconductor technologies.

 

Operating Expenses

 

Our operating expenses consist of general and administrative and research and development expenses. Third-party consulting services are the most significant component of each category of operating expenses. Operating expenses also include allocated overhead costs for facilities and utility costs.

 

Research and Development Expense

 

Research and development expense consists primarily of prototype expenses, product strategic advisory fees, and third-party engineering and contractor support costs. The Company expects research and development expenses to increase in future periods as development activities under the JDA for the Neural I/oTM chip accelerate.

 

General and Administrative Expense

 

General and administrative expenses consist primarily of consulting fees and related expenses, legal, audit and tax, third-party professional services, and allocated overhead.

 

Other (Expense) Income

 

Other (expense) income consists of income received or expenses incurred for activities outside of our core business. Other (expense) income consists primarily of interest expense, unrealized gain/loss on marketable securities, unrealized gain/loss on digital assets, and the changes in fair value of the warrant and the derivative liability.

 

Provision for Income Taxes

 

Provision for income taxes consists of estimated income taxes due to the United States government and to the state tax authorities in jurisdictions in which we conduct business. In the case of a deferred tax asset, we reserve the entire value for future periods.

 

3

 

 

Results of Operations

 

Three months ended September 30, 2026, compared to three months ended September 30, 2025

 

The following table sets forth our results of operations for each of the periods set forth below:

 

   For the Three Months Ended September 30, 
   2026   2025   Change 
Revenue  $—   $—   $— 
Cost of goods sold   —    717,120    (717,120)
Gross loss   —    (717,120)   717,120 
Operating expenses:               
Research and development   9,352,874    343,556    9,009,318 
General and administrative   3,156,979    2,472,964    684,015 
Total operating expenses   12,509,853    2,816,520    9,693,333 
Loss from operations   (12,509,853)   (3,533,640)   (8,976,213)
Other income (expense):               
Interest income   62,025    61,956    69 
Change in fair value - warrant liability   —    547,000    (547,000)
Change in fair value - derivative liability   —    179,000    (179,000)
Change in fair value – anti-dilution liability   7,412,199    —    7,412,199 
Unrealized gain (loss) on marketable securities   36,315    (37,119)   73,434 
Change in fair value of digital assets   —    (228,972)   228,972 
Realized gain on marketable securities   91,811    82,345    9,466 
Gain on sale of assets   —    —    — 
Consent and waiver fee – Series H-7   —    —    — 
Other income, net   —    171,192    (171,192)
Total other income (expense), net   7,602,350    775,402    6,826,948 
Net loss  $(4,907,503)  $(2,758,238)  $(2,149,265)

 

Cost of goods sold

 

Cost of goods sold was $0 for the three months ended September 30, 2026, as compared to $717,120 for the same period in 2025, a decrease of $717,120, or 100%. The decrease was primarily due to the absence in 2026 of the impairment charges recorded in 2025 related to inventory used in the manufacturing of the Vanish.

 

Research and development expense

 

Research and development (“R&D”) expense was $9,352,874 for the three months ended September 30, 2026, as compared to $343,556 for the same period in 2025, an increase of $9,009,318 or 2,622.4%. The increase was primarily due to expense related to the JDA, partially offset by the R&D design and re-engineering of the Vanish having been substantially completed in the prior year. The Company expects R&D expenses to increase in future periods as development activities under its the JDA for the Neural I/oTM chip accelerate.

 

General and administrative expenses

 

The majority of our operating losses from continuing operations resulted from general and administrative expenses. General and administrative expenses consist primarily of costs associated with our overall operations and with being a public company. These costs include personnel, legal and financial professional services, insurance, investor relations, and compliance related fees.

 

General and administrative expense was $3,156,979 for the three months ended September 30, 2026, compared to $2,472,964 for the same period in 2025, an increase of $684,015, or 27.7%.

 

The increase was primarily due to stock-based compensation expense of $966,491 related to stock options and restricted stock awards granted and vested during the three months ended September 30, 2026, to members of the board, our Chief Executive Officer, and a consultant, and $414,668 in warrant expense related to consulting services, compared to the same period in 2025.

 

4

 

 

Other income and expense

 

For the three months ended September 30, 2026, the Company recorded a $6,826,948 increase of other income, net. The increase for the three months ended September 30, 2026 compared to 2025 is primarily due to: (i) the Company recognizing a gain of $0 and $547,000, respectively, for the change in fair value – warrant liability; (ii) the Company recognizing a gain of $0 and $179,000, respectively, for the change in fair value – derivative liability, a decrease of $179,000, due primarily to the Series H-7 Preferred Stock being fully noticed; and (iii) the Company recognizing a gain of $7,412,199 and $0, respectively, for the change in fair value – anti-dilution liability, due to the Company’s remeasurement of the anti-dilution liability related to the Series J Preferred Stock during the three months ended September 30, 2026.

 

Nine months ended September 30, 2026, compared to nine months ended September 30, 2025

 

The following table sets forth our results of operations for each of the periods set forth below:

 

   For the Nine Months Ended September 30, 
   2026   2025   Change 
Revenue  $—   $—   $— 
Cost of goods sold   —    956,160    (956,160)
Gross loss   —    (956,160)   956,160 
Operating expenses:               
Research and development   10,167,630    1,001,237    9,166,393 
General and administrative   7,372,354    5,338,109    2,034,245 
Total operating expenses   17,539,984    6,339,346    11,200,638 
Loss from operations   (17,539,984)   (7,295,506)   (10,244,478)
Other income (expense):               
Interest income   102,620    96,157    6,463 
Change in fair value - warrant liability   —    (11,627,100)   11,627,100 
Change in fair value - derivative liability   37,000    2,840,000    (2,803,000)
Change in fair value – anti-dilution liability   (632,135)   —    (632,135)
Unrealized gain (loss) on marketable securities   90,274    (116,283)   206,557 
Change in fair value of digital assets   (538,609)   (228,972)   (309,637)
Realized gain on marketable securities   155,911    387,899    (231,988)
Gain on sale of assets   218,803    —    218,803 
Consent and waiver fee – Series H-7   —    (350,000)   350,000 
Other income, net   (1,697,889)   237,560    (1,935,449)
Total other income (expense), net   (2,264,025)   (8,760,739)   6,496,714 
Net loss  $(19,804,009)  $(16,056,245)  $(3,747,764)

 

Cost of goods sold

 

Cost of goods sold was $0 for the nine months ended September 30, 2026, as compared to $956,160 for the same period in 2025, a decrease of $956,160, or 100%. The decrease was primarily due to the absence in 2026 of the impairment charges recorded in 2025 related to inventory used in the manufacturing of the Vanish.

 

Research and development expense

 

Research and development (“R&D”) expense was $10,167,630 for the nine months ended September 30, 2026, as compared to $1,001,237 for the same period in 2025, an increase of $9,166,393 or 915.5%. The increase was primarily due to expense related to the JDA, partially offset by the R&D design and re-engineering of the Vanish having been substantially completed in the prior year. The Company expects R&D expenses to increase in future periods as development activities under the JDA for the Neural I/oTM chip accelerate.

 

General and administrative expenses

 

The majority of our operating losses from continuing operations resulted from general and administrative expenses. General and administrative expenses consist primarily of costs associated with our overall operations and with being a public company. These costs include personnel, legal and financial professional services, insurance, investor relations, and compliance related fees.

 

5

 

 

General and administrative expense was $7,372,354 for the nine months ended September 30, 2026, compared to $5,338,109 for the same period in 2025, an increase of $2,034,245, or 38.1%.

 

The increase was primarily due to stock-based compensation expense of $1,640,157 related to stock options and restricted stock awards granted and vested during the nine months ended September 30, 2026, to members of the board, our Chief Executive Officer, and a consultant, and $1,506,404 in warrant expense related to consulting services, compared to the same period in 2025. This was partially mitigated by a decrease in salaries and related consulting expenses decreasing by $789,394 for the nine months ended September 30, 2026, compared to the same period in 2025, due to the decreased headcount and shift in business direction from manufacturing.

 

Other income and expense

 

For the nine months ended September 30, 2026, the Company recorded a $6,496,714 decrease in other expense, net. The decrease for the nine months ended September 30, 2026 and compared to 2025 is primarily due to: (i) the Company recognizing a loss of $0 and $11,627,100, respectively, for the change in fair value – warrant liability, a decrease of $11,627,100, due to the Series H-7 Warrants and Series I Warrants being reclassified to equity during the year ended December 31, 2025; (ii) the Company recognizing a gain of $37,000 and $2,840,000, respectively, for the change in fair value – derivative liability, a decrease of $2,803,000, due primarily to the Series H-7 Preferred Stock being fully noticed during the nine months ended September 30, 2025; (iii) the Company recognizing a loss of $632,135 and $0, respectively, for the change in fair value – anti-dilution liability, due to the Company’s remeasurement of the anti-dilution liability related to the Series J Preferred Stock issued during the nine months ended September 30, 2026; and (iv) the Company recognizing a loss of $1,697,889 and a gain of $237,560, respectively, for other income (expense), primarily due to the $1,565,000 charge related to the Waiver Warrants issued in the nine months ended September 30, 2026.

 

Off-Balance Sheet Commitments and Arrangements

 

The Company has not entered into any off-balance sheet financial guarantees or other off-balance sheet commitments to guarantee the payment obligations of any third parties. The Company has not entered into any derivative contracts that are indexed to the Company’s shares and classified as stockholders’ equity or that are not reflected in the Company’s financial statements included in this Quarterly Report on Form 10-Q. Furthermore, the Company does not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. The Company does not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.

 

Liquidity and Capital Resources

 

Our primary uses of cash are to fund our semiconductor development activities, including our obligations under the JDA, research and development and operational staffing, and general corporate expenses. Historically, our sources of cash have consisted principally of proceeds from the sale of equity and debt securities, including preferred stock and warrants. We have incurred recurring losses from operations and expect to continue to incur net losses as we invest in the development of our technologies, and we expect our cash needs to increase as our semiconductor development activities progress.

 

As of September 30, 2026, we had $2,152,690 in cash and cash equivalents, $5,102,691 in restricted cash, $13,847,648 in marketable securities, and working capital of $18,428,403. As of December 31, 2025, we had $4,981,798 in cash and cash equivalents, $110,264 in restricted cash, $3,168,362 in marketable securities and working capital of $7,567,805.

 

As of the date of this filing, the Company had approximately $6,473,000 in cash and cash equivalents and $13,575,000 in marketable securities.

 

During the nine months ended September 30, 2026, we completed several financing transactions that materially increased our liquidity. On April 29, 2026, we closed a private placement of Series K Convertible Preferred Stock and warrants for aggregate gross proceeds of $21,500,000, of which $19,720,000 was received in net proceeds. We also entered into omnibus amendments with the holders of our Series H-7 and Series I Preferred Stock that extended the maturity dates of those securities to October 27, 2027, and removed the related installment (amortization) payment obligations. These amendments eliminated near-term mandatory cash redemption and deferred our cash needs to future periods.

 

6

 

 

Based on our current cash position and operating plan, and taking into account the additional liquidity generated by the financing transactions completed during the second quarter, management believes that our existing cash and cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months following the date of this report.

 

Our future liquidity requirements or future capital needs will depend on, among other things, capital required to fund our semiconductor technology development activities, including our obligations under the JDA, operational staffing and support requirements, as well as the timing and amount of future revenue and product costs. Our business is capital-intensive, and future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support development efforts, the results of our strategic initiatives, the timing of new product introductions and market acceptance of our future products. We are working to control expenses and deploy our capital in the most efficient manner.

 

In addition to our operating cash needs, we have obligations under the JDA with Kopin to fund initial development of the project technology, and following a successful prototype demonstration, we expect to negotiate a production plan that may require additional payments. We also have obligations associated with our outstanding preferred stock, including quarterly cash dividends and potential cash redemptions upon the occurrence of certain triggering events or a change in control, as described further below. These obligations may require the expenditure of a substantial portion of our cash resources, and if we do not have sufficient cash to satisfy them, we may need to raise additional equity or debt capital, delay, reduce or eliminate certain development programs, sell assets, or merge with another entity. We cannot provide any assurance that additional capital will be available on acceptable terms, or at all.

 

Summary of Cash Flows

 

The following table summarizes our cash flows:

 

   For the Nine Months Ended September 30, 
   2026   2025 
Cash Flows:          
Net cash used in operating activities  $(12,555,272)  $(6,045,637)
Net cash used in investing activities  $(9,151,232)  $(2,320,340)
Net cash provided by (used in) financing activities  $23,869,823   $(463,582)

 

Operating Activities

 

During the nine months ended September 30, 2026, we used $12,555,272 in cash from operating activities, an increase in use of $6,509,635 compared to the cash used in operating activities of $6,045,637 during the same period in 2025.

 

The increase in cash used in operating activities is primarily due to payments to Kopin for research and development services under the JDA, which was partially mitigated by an increase in accrued liabilities, including amounts accrued to Kopin and non-cash items reconciling net loss which consisted of stock-based compensation resulting from stock options, restricted stock awards, and consulting warrants during the nine months ended September 30, 2026, the non-cash charge related to the Waiver Warrants issued for the Series H-7 and Series I preferred stock omnibus amendment on April 27, 2026, and the anti-dilution liability in connection with the Series J Preferred Stock.

 

Investing Activities

 

During the nine months ended September 30, 2026, the Company had $9,151,232 in cash used in investing activities as compared to $2,320,340 of cash used in investing activities during the same period in 2025, an increase in cash used of $6,830,892.

 

7

 

 

The change was primarily driven by higher net purchases of marketable securities during the current period. During the nine months ended September 30, 2026, the Company invested $25,390,243 in marketable securities and received $14,957,142 in proceeds from sales of such securities, compared to $28,801,651 of purchases and $28,281,311 of proceeds during the same period in 2025. During the nine months ended September 30, 2026, the Company also received $1,410,390 of proceeds from the sale of digital assets, compared to $1,800,000 in purchases of digital assets during the same period in 2025.

 

Financing Activities

 

During the nine months ended September 30, 2026, the Company was provided cash of $23,869,823 by financing activities as compared to $463,582 cash used in financing activities for the same period in 2025, an increase in cash provided of $24,333,405.

 

The increase in cash provided was due to (i) $19,720,000 in net proceeds from the sale of the Company’s Series K Preferred Stock and (ii) $5,104,569 in proceeds from the exercises of Series H-7 Warrants and Series I Warrants during the nine months ended September 30, 2026, partially offset by warrant issuance costs of $408,357 and preferred stock dividends paid of $546,389. The Company had proceeds from the sale of Series I Preferred Stock, net of transaction costs of $6,314,297 and proceeds from exercise of Series H-7 Warrants and Series I Warrants, net of transaction costs of $1,103,648 which was offset by the payment of Series H-7 Preferred Stock Dividends and Series I Preferred Stock Dividends of $7,881,527.

 

Preferred Stock and Warrant Obligations

 

Our outstanding preferred stock and warrants give rise to obligations that may affect our liquidity and our ability to raise capital.

 

Series K Preferred Stock

 

We issued Series K Convertible Preferred Stock in April 2026 for aggregate gross proceeds of $21,500,000. Holders are entitled to cash dividends of 7% per annum, compounded quarterly, payable in arrears out of funds legally available therefor, which increase to 15% per annum, upon the occurrence and continuance of a triggering event. Upon a triggering event or a change in control, holders may require us to redeem their shares in cash at a premium, and upon certain bankruptcy events the shares become mandatorily redeemable. Our Series K Certificate of Designations also contains restrictive covenants, including a requirement to maintain minimum unencumbered cash which no longer applies because fewer than 1,050 shares of Series I Preferred Stock are outstanding, restrictions on incurring indebtedness and on redeeming or paying dividends on other capital stock, and participation rights in future offerings, which may limit our flexibility in raising capital. The Series K Preferred Stock and Series K Warrants also contain anti-dilution provisions that could increase dilution to common stockholders and make it more difficult for us to raise additional equity capital.

 

Series J Preferred Stock

 

In connection with the JDA, we issued Series J Convertible Preferred Stock to Kopin as non-cash consideration for the license to the project technology; the issuance did not provide us with any cash proceeds. Holders are entitled to dividends of 6% per annum, payable semi-annually, which we may elect to pay in cash or in kind through the issuance of additional shares of Series J Preferred Stock. The Series J Preferred Stock contains anti-dilution provisions that may require us to issue additional shares of Series J Preferred Stock to Kopin upon certain issuances of Common Stock or Common Stock Equivalents, which could increase dilution to our common stockholders and make it more difficult for us to raise additional equity capital.

 

Series H-7 Preferred Stock

 

The April 2026 amendments extended the maturity dates of our Series H-7 and Series I Preferred Stock to October 27, 2027, and removed the installment (amortization) payment obligations. During the nine months ended September 30, 2026, the holders converted the remaining 1,180 shares of Series H-7 Preferred Stock for an aggregate amount of 534,975 shares of common stock. As a result, there were no outstanding shares of Series H-7 Preferred Stock at September 30, 2026.

 

Series I Preferred Stock

 

Holders of our Series I Preferred Stock are entitled to cash dividends of 7% per annum, compounding and increasing to 15% upon a triggering event, and may require cash redemption at a premium upon the occurrence of a triggering event. Our Series I Certificate of Designations requires us to maintain unencumbered cash and cash equivalents of at least 50% of the aggregate stated value of outstanding Series I Preferred Stock. These requirements, together with the potential for cash dividends and cash redemptions upon triggering events, may require the expenditure of a substantial portion of our cash resources.

 

8

 

 

Known Trends, Events, and Uncertainties

 

The emergence and effects of public health crises, such as pandemics and epidemics, along with geopolitical conflicts, including the consequences of the ongoing war between Russia and Ukraine and between Israel and various factors in the Middle East, including related sanctions and countermeasures, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations.

 

In April 2026, the Company commenced a strategic transition toward a new business model focused on the design and development of fabless semiconductor technologies for AI data center infrastructure, including MicroLED-based optical interconnects. The Company’s ability to successfully execute this strategy is subject to significant uncertainties, including its ability to successfully develop and commercialize the Neural I/o™ chip, its dependence on Kopin Corporation for key technology and manufacturing capabilities, competition from established semiconductor companies with substantially greater resources, the evolving regulatory landscape for AI technologies and semiconductor exports, and the Company’s ability to raise sufficient capital to fund development activities. The semiconductor industry is characterized by rapid technological change, and there can be no assurance that the Company’s products, if successfully developed, will achieve market acceptance or generate revenue sufficient to sustain operations.

 

Other than as discussed above and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition.

 

Critical Accounting Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors that management believes to be relevant at the time our unaudited condensed consolidated financial statements are prepared. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.

 

We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

 

Except as described below, our critical accounting estimates have not changed materially from those previously reported in our Form 10-K. During the nine months ended September 30, 2026, in connection with our strategic transition and the JDA, we identified critical accounting estimates and judgments relating to (i) the fair value of the non-cash consideration transferred and the indefinite-lived classification and related impairment assessment of the acquired license intangible asset, (ii) the recurring fair value measurement of the anti-dilution liability, (iii) the initial fair value measurement and temporary (mezzanine) equity classification of the newly issued Series J Convertible Preferred Stock and Series K Convertible Preferred Stock, and (iv) the significant unobservable inputs used in our Level 3 fair value measurements.

 

9

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Under the supervision and with the participation of management, including our principal executive and principal financial officers, we evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were ineffective due to the material weakness in internal control over financial reporting discussed below.

 

A material weakness is a significant deficiency or a combination of significant deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

 

Material Weakness and Remediation Plan

 

As previously reported on our Annual Report on Form 10-K for the period ended December 31, 2025, we identified a material weakness in our internal control over financial reporting due to the fact that (i) we were unable to document, formalize, implement and revise where necessary controls, policies and procedure documentation to evidence a system of controls, inclusive of IT controls, including testing of such controls that is consistent with our current personnel and available resources; (ii) we failed to document, maintain and test effective control activities over our control environment, risk assessment, information technology and monitoring components; and (iii) we had insufficient segregation of duties, oversight of work performed and lack of compensating controls in our finance and accounting functions, including, without limitation, the processing, review and authorization of all routine and non-routine transactions, due to limited personnel and resources.

 

This material weakness continues to exist as of September 30, 2026.

 

Our management has been engaged in developing and implementing remediation plans to address the material weaknesses described above. Until we have sufficient technical accounting resources, we have engaged external consultants to provide support and to assist us in our evaluation of more complex applications of GAAP to aid in the remediation efforts of the material weakness.

 

We continue to enhance corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and accountability to enable remediation of our material weaknesses. As we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary.

 

Changes in Internal Control over Financial Reporting

 

Other than as described above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

10

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be involved in certain claims and litigation arising out of the ordinary course and conduct of business. Management assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the amount of loss can be reasonably estimated, provisions for loss are made based on management’s assessment of the most likely outcome.

 

The information set forth in Note 16. Commitments and Contingencies of the Notes to unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q is incorporated by reference herein.

 

There are no other material proceedings in which any of our directors, officers, affiliates, any registered or beneficial stockholder of more than 5% of our common stock, or any associate of any of the foregoing is an adverse party or has a material interest adverse to our interest.

 

ITEM 1A. RISK FACTORS

 

The following description of risk factors includes any material changes to, and supersedes the description of, risk factors associated with our business, financial condition and results of operations previously disclosed in “Item 1A. Risk Factors” of our Annual Report for the year ended December 31, 2025 on Form 10-K, as filed with the SEC on March 30, 2026. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.

 

The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Form 10-Q. The following information should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q.

 

We are a development-stage company with no revenue from our semiconductor operations and a limited operating history in the AI semiconductor industry. There can be no assurance that we will successfully develop, commercialize, or achieve market acceptance of our technologies.

 

We commenced our strategic transition toward the design and development of fabless semiconductor technologies for AI data center infrastructure in April 2026. We have a limited operating history in the AI semiconductor industry, have not generated any revenue from our semiconductor operations, and have not yet completed a prototype of our initial product, the Neural I/o™ chip. Our ability to generate revenue will depend on our successful development and commercialization of our MicroLED-based optical interconnect technology, which is subject to significant technological, engineering, and manufacturing risks. There can be no assurance that we will be able to develop products that meet their intended performance specifications, manufacture them at commercially viable cost levels, or achieve market acceptance. If we are unable to successfully execute our semiconductor strategy, our business, financial condition, and results of operations could be materially and adversely affected.

 

We are substantially dependent on our collaboration with Kopin Corporation for the development and manufacturing of our semiconductor products. If our relationship with Kopin is disrupted or terminated, our business could be materially and adversely affected.

 

Our semiconductor strategy is substantially dependent on our collaboration with Kopin Corporation pursuant to the JDA dated April 27, 2026 and the related Commercial Supply Agreement. Kopin is the sole provider of the MicroLED technology that is foundational to our Neural I/o chip. Under the Supply Agreement, all products incorporating the project technology must be manufactured exclusively by or on behalf of Kopin, and we are required to purchase our entire requirements for products from Kopin, subject to limited exceptions for supply failure events. If Kopin is unable or unwilling to continue to perform under the JDA or Supply Agreement, experiences manufacturing difficulties, fails to meet quality or delivery requirements, or if the JDA or Supply Agreement is terminated for any reason, we may be unable to develop or commercialize our products on the timelines we anticipate, or at all. In the event of termination arising from our breach, failure to fund, or a bankruptcy event, Kopin has the right to continue to develop, use, and commercialize the project technology without restriction, and we have agreed to assign to Kopin all of our right, title, and interest in the project technology. Any disruption in our relationship with Kopin could have a material adverse effect on our business, financial condition, and results of operations.

 

11

 

 

Our MicroLED-based optical interconnect technology is at an early stage of development and may not achieve the performance characteristics or cost levels necessary for commercial viability.

 

Our initial product under development, the Neural I/o chip, is at an early stage of development. We have not yet completed a prototype, and there can be no assurance that the chip will achieve its intended performance specifications, including with respect to bandwidth, latency, and power efficiency. MicroLED-based optical interconnect technology for data center applications is a nascent technology, and we face significant technical challenges in developing a commercially viable product. The development process may take longer, cost more, or encounter more technical obstacles than we currently anticipate. Even if we successfully develop a working prototype, we may face additional challenges in scaling manufacturing, achieving acceptable yield rates, and reducing per-unit costs to levels that are competitive with incumbent copper-based and laser-based interconnect solutions. If we are unable to demonstrate the technological viability of our products or bring them to market in a timely manner, our business and prospects could be materially and adversely affected.

 

We face intense competition from established semiconductor companies with significantly greater resources, and our products may not be able to compete effectively.

 

The markets for AI infrastructure and data center interconnect technologies are intensely competitive and subject to rapid technological change. We face competition from established providers of copper-based and laser-based interconnect solutions, including large, diversified semiconductor companies and specialized optical interconnect providers, many of which have significantly greater financial, technical, manufacturing, marketing, and distribution resources than we do. Many of our potential competitors have longer operating histories, larger and more established customer bases, and more extensive research and development capabilities. We may also face competition from new entrants into the MicroLED interconnect space or from alternative technologies that we have not yet anticipated. If our competitors develop technologies that are superior to ours, or if they are able to bring competing products to market before us, our ability to achieve market acceptance could be significantly impaired, which would materially and adversely affect our business and results of operations.

 

We will require substantial additional capital to fund our semiconductor development activities, and there can be no assurance that such capital will be available on acceptable terms, or at all.

 

Our semiconductor development activities will require substantial capital investment. Pursuant to the JDA, we have agreed to pay Kopin up to $15,000,000 for the initial development of the project technology, and following a successful prototype demonstration, the parties expect to negotiate a production plan that may include an additional payment by us of approximately $15,000,000 to $25,000,000. In addition to our obligations under the JDA, we expect to incur significant costs related to research and development, personnel, equipment, and general corporate activities as we scale our operations. While we have raised significant funds through recent financing transactions, these funds may not be sufficient to fund our development activities through commercialization. If we are unable to raise additional capital when needed, we may be required to delay, reduce, or eliminate certain development programs, which could materially and adversely affect our business, financial condition, and prospects.

 

Our semiconductor products may be subject to export control restrictions and trade regulations that could limit our ability to sell products internationally or collaborate with foreign partners.

 

The design, development, and potential sale of semiconductor technologies for AI data center applications are subject to U.S. export control laws and regulations, including the Export Administration Regulations administered by the Bureau of Industry and Security and economic sanctions programs administered by the Office of Foreign Assets Control. The U.S. government has significantly expanded export controls applicable to advanced semiconductor technologies, AI-related hardware, and supercomputing components in recent years. If our products, once developed, are classified under export-controlled categories, we may be required to obtain licenses or authorizations prior to export, and certain destinations, entities, or end uses may be prohibited entirely. Changes to export control regulations, the Entity List, or the imposition of new sanctions could limit our ability to sell products in key international markets, restrict our ability to collaborate with foreign partners or contract manufacturers, or otherwise materially and adversely affect our business.

 

12

 

 

Environmental, health and safety (EHS) laws and regulations may expose us to liability, and such liability and compliance with these laws and regulations may adversely affect our business.

 

The semiconductor industry is subject to a variety of international, federal, state, local and non-U.S. laws and regulations governing pollution, environmental protection and occupational health and safety, including those relating to the release, storage, use, discharge, handling, generation, transportation, disposal, and labeling of, and human exposure to, hazardous and toxic materials, product composition, and the investigation and cleanup of contaminated sites, including sites we currently or formerly owned or operated, due to the release of hazardous materials, regardless of whether we caused such release. We are also required to obtain environmental permits from governmental authorities for some of our operations. We cannot be assured that we have been or will be at all times in complete compliance with such EHS laws, regulations and permits. Failure to comply with such EHS laws and regulations could subject us to civil or criminal costs, obligations, sanctions or property damage or personal injury claims, or suspension of our facilities’ operating permits.

 

Changes in EHS laws or regulations may require us to invest in costly equipment or make manufacturing process changes and may adversely affect the sourcing, supply and pricing of materials used in our products. We believe that our model of a fabless company minimizes those risks, although any such changes may require us to conduct careful audits of our vendors or even to replace vendors, which may involve costs in qualifying or making adjustments for the work with another vendor.

 

In the event of an incident involving hazardous materials, we could be liable for damages and such liability could exceed the amount of any liability insurance coverage and the resources of our business. In addition, in the event of the discovery of contaminants or the imposition of clean up obligations for which we are responsible, we may be required to take remedial or other measures which could have a material adverse effect on our business, financial condition and results of operations. In response to environmental concerns, some customers and government agencies impose requirements for the elimination and/or labeling of hazardous substances, such as lead (which is widely used in soldering connections in the process of semiconductor packaging and assembly), in electronic equipment, as well as requirements related to the take-back of products discarded by customers.

 

EHS laws and regulations have tended to become more stringent over time, causing a need to redesign technologies, imposing greater compliance costs and increasing risks and penalties associated with violations, which could seriously harm our business.

 

In addition, increasingly regulators, customers, investors, employees and other stakeholders are focusing on environmental, social and governance (ESG) matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations.

 

We have no full-time employees and rely heavily on consultants and contractors, which may limit our ability to execute our business strategy.

 

As of September 30, 2026, we had zero full-time employees and rely on consultants and contractors to supplement our capabilities. Our future success depends in significant part on our ability to attract, retain, and motivate qualified engineering, scientific, and management personnel. Competition for such personnel in the semiconductor industry is intense, and we may not be able to attract or retain the personnel necessary to execute our semiconductor development strategy. Our reliance on consultants and contractors may also create challenges related to intellectual property protection, continuity of institutional knowledge, and the consistent execution of our development programs. If we are unable to build and maintain an adequate team to support our operations, our business and results of operations could be materially and adversely affected.

 

Our fabless business model makes us dependent on third-party manufacturers, and our business may be adversely affected by supply chain disruptions, tariffs, or geopolitical risks.

 

We operate as a fabless semiconductor company and intend to outsource the fabrication and manufacturing of our chips to third-party contract manufacturers. This model makes us dependent on the manufacturing capacity, quality, and timeliness of our manufacturing partners. A significant portion of global semiconductor manufacturing capacity is concentrated in Asia, and trade tensions between the United States and certain countries have resulted in increased tariffs, export restrictions, and supply chain disruption risk. Changes in trade policy, the imposition of new or increased tariffs on semiconductor components or materials, or disruption of international supply chains could increase our costs, limit access to manufacturing partners, or delay product development and commercialization. Additionally, our dependence on Kopin as the exclusive manufacturer of products incorporating the project technology means that any disruption to Kopin’s manufacturing capabilities could directly and materially impact our ability to deliver products to customers.

 

13

 

 

Because we operate a fabless business model, we may not be eligible for certain U.S. government incentives and tax credits offered to promote domestic semiconductor production.

 

From time to time, governments may provide subsidies or make other investments that could give competitive advantages to certain semiconductor companies. For example, in 2022, the U.S. government passed the Creating Helpful Incentives to Produce Semiconductors & Sciences Act to provide $52.7 billion of funding to U.S.-based semiconductor companies to promote domestic production. Because we operate a fabless business model, we may not be eligible for such incentives from the U.S. government at this time.

 

We jointly own intellectual property developed under our collaboration with Kopin, and our dependence on Kopin’s existing intellectual property may limit our ability to independently commercialize our technology.

 

Intellectual property developed through our collaboration with Kopin is jointly owned by both companies. Our technology leverages Kopin’s patented bi-directional NeuralDisplay™ architecture, and we are dependent on Kopin’s existing intellectual property portfolio as a foundation for our product development. While Kopin has granted us a non-exclusive, royalty-free, worldwide license under its background technology for developing and commercializing the project technology, we do not have sole ownership or exclusive rights to much of the intellectual property underlying our products. If our relationship with Kopin deteriorates, or if Kopin’s intellectual property rights are challenged or invalidated by third parties, our ability to develop and commercialize our products could be materially impaired. Additionally, we may face claims of intellectual property infringement from third parties, particularly given the competitive nature of the semiconductor industry, and defending against such claims could be costly and time-consuming.

 

Holders of our shares of Series K Preferred Stock are entitled to certain payments under the Series K Certificate of Designations that may be paid in cash, which may require the expenditure of a substantial portion of our cash resources.

 

The holders of the Series K Preferred Stock are entitled to dividends of 7% per annum (“Dividends”), compounded each calendar quarter, which are payable in arrears on the first trading day of each calendar quarter (each, a “Dividend Date”), with the first Dividend Date being July 1, 2026, in cash out of funds legally available therefor; provided that a holder of the Series K Preferred Stock and the Company may mutually agree to convert any Dividends into shares of Common Stock at a price to be mutually determined by the Company and such holder, which shall not be less than the lower of (x) $0.502, which was 20% of the “Minimum Price” (as defined in Rule 5635 of the Nasdaq Stock Market) on the date of the Purchase Agreement and (y) $3.57, which was 20% of the “Minimum Price” (as defined in Rule 5635 of the Nasdaq Stock Market) on June 18, 2026, the date on which our stockholders approved the issuance of shares of Common Stock in excess of 19.99% of our outstanding shares (the “Stockholder Approval Date”), in each case, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events, or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Capital Market (the “Floor Price”). Upon the occurrence and during the continuance of a Triggering Event (as defined in the Series K Certificate of Designations), the Series K Preferred Stock accrue dividends at the rate of 15% per annum. In connection with a Triggering Event, each holder of Series K Preferred Stock will be able to require us to redeem in cash any or all of the holder’s Series K Preferred Stock at a premium set forth in the Series K Certificate of Designations. If such Triggering Event occurs, our financial condition and results of operations could be materially affected.

 

If we do not have sufficient cash resources to make these payments, we may need to raise additional equity or debt capital, and we cannot provide any assurance that we will be successful in doing so. If we are unable to raise sufficient capital to meet our payment obligations, we may need to delay, reduce or eliminate certain research and development programs or other operations, sell some or all of our assets or merge with another entity. Our ability to make payments due to the holders of our Series K Preferred Stock using cash is also limited by the amount of cash we have on hand at the time such payments are due as well as certain provisions of the Delaware General Corporation Law.

 

14

 

 

The Series K Preferred Stock and the Series K Warrants contain certain anti-dilution provisions, which may dilute the interests of our stockholders, depress the price of our common stock, and make it difficult for us to raise additional capital.

 

Certain events, for example, a Stock Combination Event (as defined in each of the Series K Certificate of Designations and the Series K Warrants) may reduce the conversion price of the Series K Preferred Stock and the exercise price of the Series K Warrants, which in turn may lead to further dilution to the holders of our Common Stock. The Series K Warrants additionally contain anti-dilution provisions applicable to the exercise price. If in the future, while any of the Series K Warrants are outstanding, we may be required upon the occurrence of certain events, to adjust the exercise price of the Series K Warrants, and simultaneously with any adjustment to the exercise price, the number of shares of Common Stock that may be purchased upon exercise of the Series K Warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable thereunder for the adjusted number of shares of Common Stock issuable upon exercise of the Series K Warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. Such adjustments can dilute the book value per share of Common Stock and reduce any proceeds we may receive from the exercise of the Series K Warrants. In addition, the perceived risk of dilution may cause our shareholders to be more inclined to sell their Common Stock, which may in turn depress the price of common shares regardless of our business performance. We may also find it more difficult to raise additional equity capital while any of the Series K Warrants and the Series K Preferred Stock remain outstanding.

 

The Series K Certificate of Designations contains restrictive covenants and terms that may make it difficult to procure additional financing and that may affect our financial condition and results of operations.

 

The Series K Certificate of Designations contains certain restrictive covenants including but not limited to: maintaining a minimum amount of unencumbered, unrestricted cash and cash equivalents on hand, until the date on which less than 1,050 shares of the Series I Preferred Stock are outstanding; restrictions on incurring any indebtedness until the date on which no shares of Series I Preferred Stock are outstanding, subject to certain exceptions; restrictions on directly or indirectly, redeeming, repurchasing or declaring or paying any cash dividend or distribution on any of our capital stock (other than as required by the Series K Certificate of Designations, the Certificate of Designations of our Series A Junior Participating Preferred Stock, the Series H-7 Certificate of Designations, the Series I Certificate of Designations and Series J Certificate of Designations), and restrictions on directly or indirectly, permitting any of our indebtedness to mature or accelerate prior to the Maturity Date (as defined in the Series K Certificate of Designations). Additionally, the Series K Preferred Stock also contain certain purchase rights (the “Purchase Rights”) permitting the holders of the Series K Preferred Stock to acquire upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder had held the number of shares of Common Stock acquirable upon complete conversion of all of its shares of Series K Preferred Stock. These restrictive covenants may limit our flexibility in raising capital or incurring any indebtedness, which may have an adverse effect on our financial condition.

 

Under the Series K Purchase Agreement, we are subject to certain restrictive covenants that may make it difficult to procure additional financing.

 

The Series K Purchase Agreement contains, among others, the following restrictive covenants: (A) until all of the Series K Warrants are no longer outstanding, we shall be prohibited from effecting or entering into an agreement to effect any subsequent placement involving a variable rate transaction, and (B) until the date in which no shares of Series K Preferred Stock remain outstanding, the Company must provide the holders of the shares of Series K Preferred Stock the opportunity to participate in any subsequent securities offerings by us.

 

If we require additional funding while these restrictive covenants remain in effect, we may be unable to effect a financing transaction on terms acceptable to us, or at all, while also remaining in compliance with the terms of the Series K Purchase Agreement, or we may be forced to seek a waiver from the investors party to the Series K Purchase Agreement, which such investors are not obligated to grant to us.

 

15

 

 

The Series J Preferred Stock and related anti-dilution provisions may result in significant dilution to our common stockholders and may limit our operational and financial flexibility.

 

Pursuant to the JDA, the Company agreed to issue to Kopin shares of Series J Preferred Stock constituting 19.9% of the pro forma fully diluted outstanding shares of Common Stock, convertible at the Series J Conversion Price of $2.51 per share. The Series J Certificate of Designations provides that the Maximum Issuance (as defined in the Series J Certificate of Designations) shall be increased upon the occurrence of Dilutive Issuances or Dilutive Conversions by 0.1999 shares of Common Stock for each share of Common Stock issued in connection with such events, until adjustments have been made with respect to an aggregate of $50 million in such issuances. The Company has agreed to take all actions necessary to give full force and effect to these adjustment provisions, including through the issuance of additional shares of Series J Preferred Stock to Kopin. In addition, the Series J Preferred Stock accrues dividends at 6% per annum, payable semi-annually on each Dividend Payment Date, which may be paid as a PIK Dividend through the issuance of additional shares of Series J Preferred Stock having an aggregate stated value equal to the amount of the dividend then due, further increasing the number of shares of Common Stock issuable upon conversion. Without the prior express consent of the Required Holders, the Company may not, among other things, amend its Charter or Bylaws in ways that would adversely affect the Series J Preferred Stock, create or authorize new Senior Preferred Stock or Parity Stock, purchase or redeem Junior Stock, or pay dividends on Junior Stock. These protective provisions, together with the potential for significant dilution from anti-dilution adjustments and PIK Dividends, may restrict the Company’s ability to pursue certain corporate transactions or capital raising activities, depress the market price of the Company’s Common Stock, and make it more difficult for the Company to raise additional capital on favorable terms.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

No unregistered securities were sold during the three months ended September 30, 2026, other than as reported in our Current Reports on Form 8-K filed with the SEC.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

Rule 10b5-1 Trading Arrangements

 

None of the Company’s officers or directors adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended September 30, 2026, as such terms are defined under Item 408(a) of Regulation S-K.

 

16

 

 

ITEM 6. EXHIBITS

 

Exhibit
No.
  Description
     
10.1   Consulting Services Agreement, dated August 13, 2026, by and between the Company and Michael Murray (incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2026).
     
31.1**   Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2**   Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2*   Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101 INS**   Inline XBRL Instance Document
101 SCH**   Inline XBRL Taxonomy Extension Schema Document
101 CAL**   Inline XBRL Taxonomy Calculation Linkbase Document
101 DEF**   Inline XBRL Taxonomy Extension Definition Linkbase Document
101 LAB**   Inline XBRL Taxonomy Labels Linkbase Document
101 PRE**   Inline XBRL Taxonomy Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

**   Filed herewith.
*   Furnished herewith.

 

17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  FABRIC.AI, INC.
     
Dated: November 13, 2026 By: /s/ Joshua Silverman
    Joshua Silverman
    Chief Executive Officer
    (Principal Executive Officer)

 

Dated: November 13, 2026 By: /s/ Joseph Ramelli
    Joseph Ramelli
    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)

 

18

 

Keep reading